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ABSTRACT 
MASS SPECTROMETRIC CHARACTERIZATION AND IMAGING OF 
NANOPARTICLES IN BIOLOGICAL SAMPLES  
 
MAY 2014 
 
BO YAN 
 
B.S., PEKING UNIVERSITY 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard W. Vachet and Professor Vincent M. Rotello 
 
Nanoparticles (NPs) are being investigated widely for use in biomedical applications 
such as imaging, drug delivery, and cancer therapy due to their small size and readily 
tunable properties. The ability to accurately characterize NPs and monitor their spatial 
distributions is highly desirable for effective use of NPs and evaluation of their potential 
adverse environmental, health, and safety effects. In this dissertation, a simple, fast, and 
sensitive method based on laser desorption/ionization mass spectrometry (LDI-MS) to 
characterize and track NPs in biological systems has been developed. This method is 
especially well suited for characterizing core-shell structured NPs, such as quantum dots 
(QDs), gold NPs (AuNPs) and magnetic NPs, in a variety of sample types. The surface 
functionalities attached to the cores of the NPs can be qualitatively and quantitatively 
analyzed by LDI-MS with ultra-low sample consumption. A new molecular imaging 
technique has been developed based on the LDI-MS detection of NPs. Tissues from mice 
injected with NPs can be obtained and readily imaged to identify the location of NPs in 
these tissues. NPs can be selectively detected in a multiplexed fashion in tissues and the 
intra-organ distributions of same-sized NPs are directly linked to their surface 
functionality. 
 
 
 
 vii 
 
 
TABLE OF CONTENTS 
 
 Page 
 
ACKNOWLEDGMENTS ...................................................................................................v 
ABSTRACT ....................................................................................................................... vi 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES .............................................................................................................x 
CHAPTER 
1. INTRODUCTION ...........................................................................................................1 
1.1 Nanoparticles and biomedical applications .......................................................1 
1.2 Characterization of monolayer-protected NPs ...................................................4 
1.3 Mass spectrometric characterization of NPs ......................................................5 
1.4 Detection of NPs ................................................................................................7 
1.5 New developments in LDI-MS for the detection of NPs .................................10 
1.6 Imaging NPs using LDI-MS ............................................................................12 
1.7 Dissertation overview ......................................................................................14 
1.8 References ........................................................................................................16 
2. LASER DESORPTION/IONIZATION MASS SPECTROMETRY ANALYSIS OF 
MONOLAYER PROTECTED GOLD NANOPARTICLES ........................................24 
2.1 Introduction ......................................................................................................24 
2.2 Results and discussion .....................................................................................27 
2.3 Conclusions ......................................................................................................40 
2.4 Experimental section ........................................................................................40 
2.5 Supporting information ....................................................................................42 
2.6 References ........................................................................................................48 
3. CHARACTERIZATION OF SURFACE LIGANDS ON FUNCTIONALIZED 
MAGNETIC NANOPARTICLES USING LASER DESORPTION/IONIZATION 
MASS SPECTROMETRY ............................................................................................51 
3.1 Introduction ......................................................................................................51 
3.2 Results and discussion .....................................................................................53 
3.3 Conclusions ......................................................................................................61 
3.4 Experimental section ........................................................................................62 
 viii 
3.5 Supporting information ....................................................................................65 
3.6 References ........................................................................................................67 
4. MASS SPECTROMETRIC DETECTION OF NANOPARTICLE HOST-GUEST 
INTERACTIONS IN CELLS ........................................................................................70 
4.1 Introduction ......................................................................................................70 
4.2 Results and discussion .....................................................................................72 
4.3 Conclusions ......................................................................................................79 
4.4 Experimental Section .......................................................................................80 
4.5 Supporting Information ....................................................................................82 
4.6 References ........................................................................................................85 
5. LASER DESORPTION IONIZATION MASS SPECTROMETRIC IMAGING OF 
MASS BARCODED GOLD NANOPARTICLES ........................................................88 
5.1 Introduction ......................................................................................................88 
5.2 Results and discussion .....................................................................................90 
5.3 Conclusions ......................................................................................................95 
5.4 Experimental section ........................................................................................96 
5.5 Supporting information ....................................................................................97 
5.6 References ........................................................................................................98 
6. MULTIPLEXED IMAGING OF NANOPARTICLES IN TISSUES USING LASER 
DESORPTION/IONIZATION MASS SPECTROMETRY ........................................101 
6.1 Introduction ....................................................................................................101 
6.2 Results and discussion ...................................................................................103 
6.3 Conclusions ....................................................................................................111 
6.4 Experimental section ......................................................................................112 
6.5 Supporting information ..................................................................................116 
6.6 References ......................................................................................................119 
BIBLIOGRAPHY ............................................................................................................123 
 
 ix 
 
LIST OF TABLES 
Table Page 
1.1. Characteristics, ligands and representative applications for various metal and 
semiconductor materials. .......................................................................... 3 
2.1. A summary of the dominant ions observed in the LDI mass spectrum of the 
AuNPs shown in Figure 2.1. ................................................................... 33 
3.1. HPLC-MS quantification of ligand composition in mixed monolayer 
magnetic FePt NPs .................................................................................. 66 
3.2. 3-day reproducibility of the LDI-MS technique ...................................................... 67 
4.1. Detail p values for the comparison between different NP-CB[7] complexes. ......... 84 
4.2. Ion intensity ratios of AuNP-CB[7] complexes in solutions using MALDI-
MS. .......................................................................................................... 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 x 
 
LIST OF FIGURES 
Figure Page 
1.1. Various types of NPs have been developed for cancer therapy. Cartoon key: 
(a) polymeric nanogel, (b) polymeric micelle, (c) gold NP (AuNP), 
(d) iron oxide NP, (e) siRNA ensconced in a liposome delivery 
vector, and (f) a stimuli-responsive capped mesoporous silica NP. 
(Reproduced from Ref. 21) ....................................................................... 2 
1.2. Schematic demonstration of monolayer-protected NPs. (a) Schematic 
representation of a 2 nm AuNP with 11-mercaptoundecanoic acid 
monolayer and relative sizes of papain and a 24-mer DNA duplex. 
(b) Design and function of the SAMs on NP cores. ................................. 4 
1.3. AuNPs uptake by plants after 5-day treatments: AuNP amounts found in the 
roots (a) and shoots (b) of four different plants. The plants were 
each exposed to 30 nM AuNPs (1-3) for 5 days. The means are 
averaged from at least six replicates, except in the case of the 
pumpkin where only three replicate experiments were conducted. 
Error bars correspond to standard error of the mean. * P ≤ 0.05, 
** P ≤ 0.01, *** P ≤ 0.001 from unpaired t-tests between the 
control and AuNP treated groups. (c) Translocation factors (TF %, 
[Au] in shoots/[Au] in KI/I2 etched roots) of AuNPs in different 
plant species. (d) Structural illustrations of the AuNPs used in this 
study. ......................................................................................................... 9 
1.4. Scheme of LDI-MS characterization process of surface ligands on NPs. ............... 11 
2.1. Structural representations of the AuNPs used in this study. .................................... 27 
2.2. LDI mass spectra of (a) AuNP 1, (b) AuNP 2 and (c) AuNP 3. In each case, 
M corresponds to the ligand exactly as it is shown in Figure 2.1. 
The ligand fragment ions corresponding to losses of methylene 
groups are labeled as B, and the ligand fragment ions 
corresponding to losses of ethylene glycol units are labeled as A. 
The peak in spectrum (c) labeled with an asterisk (*) corresponds 
to tetraoctylammonium (TOAB), which is an impurity that remains 
from the synthesis. In spectra (a) and (c), the small peaks 
corresponding to disulfides with the initial pentanethiol capping 
group (i.e. C5H11S) are only observed when the initial ligand 
exchange reaction in solution is incomplete. .......................................... 29 
2.3. (a) Structures of the disulfide ion of AuNP 7 and its two main fragment ions; 
(b) LDI mass spectrum of AuNP 7. ........................................................ 31 
 xi 
2.4. LDI mass spectra of (a) mixed monolayer AuNP with both TTMA and 
TEGOH on the surface (MMNP 1); (b) mixed monolayer AuNP 
with both TEGOH and TEGOH on the surface (MMNP 2); (c) 
mixture of AuNP 2 (TEGOH ligand) and AuNP 1 (TTMA ligand); 
(d) mixture of AuNP 2 (TEGOH ligand) and AuNP 3 (TEGCOOH 
ligand). .................................................................................................... 36 
2.5. (a) Comparison of ratios between ions from TTMA ligand and TEGOH 
ligand: I403/(I403+I422) (red line), I369/(I369+I388) (blue line), and 
(I369+I403)/(I403+I422+I369+I388) (black line). (b) Comparison of 
ratios between disulfide ions from TTMA ligand and TEGOH 
ligand: I782/(I782+I827) (red line), I801/(I801+I782) (blue line), and 
I801/(I801+I827) (black line). (c) Comparison of LDI-MS (red line) 
and MALDI-MS (blue line) for the I801/(I801+I827) ratio. The 
equation for the LDI-MS fit is, y = 1.07x + 0.08, R
2
=0.968. The 
equation for the MALDI-MS fit is, y = 0.61x + 0.53, R
2
=0.817. ........... 39 
2.6. LDI mass spectrum of AuNP 1 in cell lysate of cultured monkey kidney cells 
(COS-1). The peak labeled “#” is the molecular ion corresponding 
to the head-group fragment of phosphatidylcholine (m/z 184), 
which is an abundant lipid in the cell membrane of the COS-1 
cells. ........................................................................................................ 39 
2.7. TEM imaging of AuNPs: (left) pentanethiol-coated AuNP (the precursor 
AuNP for AuNP 1, 3-15 and MMAuNPs before doing ligands 
exchange reactions); (right) AuNP 2. ..................................................... 42 
2.8. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(10:90). .................................................................................................... 43 
2.9. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(26:74). .................................................................................................... 44 
2.10. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(44:56). .................................................................................................... 45 
2.11. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(68:32). .................................................................................................... 46 
2.12. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(83:17). .................................................................................................... 47 
3.1. Scheme of the structural and quantitative characterization of the ligands 
attached to MNP by LDI-MS. ................................................................. 53 
 xii 
3.2. (a) TEM image of FePt NPs (scale bar = 20 nm). (b) FePt NP size distribution 
(100 FePt NPs), core size of FePt NPs 4.0 ± 0.4 nm. (c) Ligands 
used for FePt NPs. (d) TEM image of Fe3O4 NPs (scale bar = 20 
nm). (e) Fe3O4 NP size distribution (100 Fe3O4 NPs), core size of 
Fe3O4 NPs 3.9 ± 0.5 nm. (f) Ligands used for Fe3O4 NPs. ..................... 54 
3.3. LDI mass spectra of (a) FePt NP with ligand T, (b) FePt NP with ligand D, 
and (c) mixed-monolayer FePt NPs with both T and D. The ligand 
T fragment ions corresponding to the losses of methylene groups 
are labelled as A, and the ligand T fragment ions corresponding to 
the losses of ethylene glycol units are labelled as B. The ligand D 
fragment ions corresponding to the losses of methylene groups are 
labelled as C. The symbol @ in red (non-italic) corresponds to the 
ions generated from ligand T while the symbol # in blue (italic) 
indicates ions from ligand D. .................................................................. 56 
3.4. LDI-MS fragmentation pattern of ligand D on the FePt NPs. ................................. 57 
3.5. (a) Structures of ligands. (b) LDI mass spectrum of the mixed-monolayer 
Fe3O4 NPs. The m/z ratios in red or marked # correspond to the 
ions generated from the ligand H, while the m/z ratios in blue or 
marked @ (italic) indicate ions from the ligand M. Fragments 
generated from both ligand H and ligand M are labelled using (!). ....... 58 
3.6. LDI-MS fragmentation pattern of ligand M and ligand H on FePt NPs ................. 58 
3.7. LDI-MS analysis of a 1:1 mixture of FePt NPs with ligand D and T. .................... 59 
3.8. LDI-MS and HPLC-MS measurements of surface ligand composition for the 
mixed-monolayer FePt NPs. ................................................................... 60 
3.9. Representative LDI-MS analysis of mixed monolayer FePt NPs with various 
amount of ligand D (blue, italic) and T (red, non-italic). ....................... 61 
3.10. Representative LDI mass spectra of Fe3O4 NPs with various amount of 
ligand H and M. The fragmentation patterns can be found in 
Figure 3.6. Selected representative ions have been marked as 
below: the m/z ratios in red or marked # correspond to the ions 
generated from the ligand H, while the m/z ratios in blue or marked 
@ (italic) indicate ions from the ligand M. Some of the fragments 
from Ligand H and M may overlapped in the mass spectra of 
mixed monolayer Fe3O4 NPs, and those ions are labelled using 
(!).Some contamination ions generated from the trace amount of 
gold on the sample target have been marked + in the mass 
spectrum of Fe3O4 NP with Ligand M. ................................................... 65 
 xiii 
3.11. LDI mass spectra of Fe3O4 NPs with other ligands. .............................................. 66 
4.1. (a) Schematic illustration of the MALDI-MS detection process of 
supramolecular complexes in cells. (b) Monitoring the selective 
dissociation of the supra-molecular complexes after adding the 
competitive binding molecule ADA. ...................................................... 72 
4.2. (a) Chemical structures of the surface functionalities on the AuNPs used in 
this work. (b) The theoretical mass-to-charge (m/z) ratios of 
ligands and their corresponding supramolecular complexes 
detected by MALDI-MS. ........................................................................ 73 
4.3. Monitoring AuNP-CB[7] interaction in solutions using MALDI-MS. (a) 
AuNP 1-CB[7]. (b) AuNP 2-CB[7]. (c) AuNP 3-CB[7]. ....................... 74 
4.4 Monitoring AuNP-CB[7] interaction using MALDI-MS. (a) Detection of 
AuNP 1 in cells. (b) Detection of AuNP 1-CB[7] uptaken by the 
cells. (c) Monitor the dissociation of the host-guest complex by 
adding ADA to the cells containing AuNP 1-CB[7]. ............................. 76 
4.5. Monitoring the dissociation of three AuNP-CB[7] complexes in cells. (a) 
Typical mass spectrum of cell samples incubated with a mixture of 
three AuNP-CB[7] complexes. (b) Normalized ion intensity ratios 
indicating the relative amount of the remaining supramolecular 
complexes after the ADA treatments. n.s., no significant 
difference. **, 0.001<P≤0.01; ***, P≤0.001 through one-way 
ANOVA (n=9). ....................................................................................... 78 
4.6. Estimation of the remaining complexes in the cell lysates. ..................................... 79 
4.8. Mass spectra of the AuNP-CB[7] complexes. (a) AuNP 4-CB[7]. (b) AuNP 
5-CB[7]. (c) AuNP 6-CB[7]. (d) AuNP 7-CB[7]. .................................. 83 
4.9. Cellular uptake amount per well of AuNP-CB[7] complexes measured by 
ICP-MS. .................................................................................................. 84 
4.10. TEM image of pentanethiol (C5) coated AuNPs. .................................................. 84 
5.1. Schematic illustration of the anti-counterfeiting inkjet printing strategy used 
in this work. ............................................................................................ 90 
5.2. Mass spectra of the four nanoparticles used in this study, with the m/z value 
used for scanning highlighted. ................................................................ 91 
5.3. (a) The Au
+
 distribution determined by scanning the ITO coated glass 
surface. (b)  The Au2
+
 distribution determined by scanning the ITO 
 xiv 
coated glass surface. (c) The signal distribution of the ligand on 
AuNP 1 determined by scanning the ITO coated glass. (Detected 
ions: Au
+
 m/z = 197, Au2
+
 m/z = 394, AuNP 1 ligand m/z = 422). ......... 92 
5.4. LDI-IMS images for the various ligands tinted different colors for viewing. 
(a) AuNP 1, (b) AuNP 3, (c) AuNP 2, and (d) AuNP 4. (e) All 4 
signals combined showing the completed pattern. ................................. 94 
5.5. Overlapped two channel printing. MSI of overlapped printing AuNPs, 
detected ions: blue letters AMHERST (AuNP 4 m/z = 548), green 
letters UMASS (AuNP 1 m/z = 422), red pattern (Au
+
 m/z = 197). ....... 95 
5.6. Screen capture of the pattern to be printed on the substrate. ................................... 97 
5.7.  A LDI-MS image of the logo of the NSF Center for Hierarchical 
Manufacturing printed using AuNPs. ..................................................... 98 
6.1. Workflow for the LDI-MS imaging strategy to obtain the biodistributions of 
multiple AuNPs in mouse tissues. ........................................................ 103 
6.2. Structures of the surface monolayers on the AuNPs used in this study: the 
“mass barcode” is the m/z of the AuNP surface ligand. ....................... 103 
6.3. Characterization of AuNP 1-3. TEM images of the AuNPs after the Murray 
place-exchange reactions: (a) AuNP 1; (b) AuNP 2; and (c) AuNP 
3. Core size distribution of each AuNP: (d) AuNP 1; (e) AuNP 2; 
and (f) AuNP 3 (120 NPs were randomly selected). (g) One-way 
ANOVA test indicates the same core size of these AuNPs (n = 
120). (h) Overall size distribution of three AuNPs (360 NPs). The 
hydrodynamic size of each AuNP was measured by dynamic light 
scattering (DLS): (i) AuNP 1; (j) AuNP 2; and (k) AuNP 3. Zeta-
potential measurements of the AuNPs are shown in panel (l) AuNP 
1; (m) AuNP 2; and (n) AuNP 3. .......................................................... 104 
6.4. LDI-MS characterization of (a) AuNP 1; (b) AuNP 2, and (c) AuNP 3. The 
LDI-MS results are consistent with previous research.
24,25,27
 
Symbol key: +, Au
+
 (m/z 197); ++, Au2
+
 (m/z 394); +++, Au3
+
 (m/z 
591); MH
+
, the molecular ion corresponding to surface ligand; A, a 
fragment ion corresponding to a loss of H2S ([MH-H2S]
+
) from the 
intact ligand; B, ions corresponding to multiple losses of 
methylene groups from the alkane portion of the ligands; C, ions 
corresponding to multiple losses of ethylene glycol groups from 
the ligands. ............................................................................................ 105 
6.5. AuNP amounts in different organs as determined by ICP-MS. The AuNP 
concentrations were calculated by the gold amount (ng) divided by 
 xv 
organ weight (g) (± standard error of the mean). (control group: n 
= 3, experimental group: n = 4). ........................................................... 106 
6.6. Representative LDI mass spectra of AuNPs in mouse spleen. (a) AuNP 1 
(molecular ion m/z = 436). (b) AuNP 2 (molecular ion m/z = 492). 
(c) AuNP 3 (molecular ion m/z = 548). Other ions in the spectra 
correspond to fragments of the phosphatidylcholine head groups 
(m/z 184, 202, and 230), which are indicated with *, and Au
+
 (m/z 
197), which is indicated by a +. ............................................................ 107 
6.7. LDI-MS on spleen tissue from mouse injected with DPBS buffer. Control 
experiments to confirm that the “mass barcodes” of AuNPs are 
only observed when the ligands are attached on the gold cores. (a) 
Typical LDI mass spectrum of spleen tissues from a mouse that 
was not injected with AuNPs. (b) Typical LDI mass spectrum of a 
tissue slice from a non-injected mouse that was spiked with free 
ligands (1 μL of 5 μM ligand mixture solution). (c) Example LDI 
mass spectrum of a spleen slice from a non-injected mouse that 
was spiked with 1 μL of a 50 nM mixture of AuNP 1, AuNP 2, and 
AuNP 3. Symbol key: *, ions from phosphatidylcholine head 
groups; +, gold ions; #, interference ions from the ITO glass slide; 
F1 and F2, fragment ions corresponding to a loss of H2S ([MH-
H2S]
+
) from molecular ions of ligands on AuNP 1 and 2, 
respectively. .......................................................................................... 108 
6.8. LDI-MS images of AuNPs in mouse spleens. The biodistributions of AuNPs 
are shown in panel (a) AuNP 1, (b) AuNP 2, and (c) AuNP 3. Ions 
selected for image generation: AuNP 1 m/z 436, AuNP 2 m/z 492, 
and AuNP 3 m/z 548. Scale bar represents 500 µm. ............................. 109 
6.9. LDI-MS images of spleens from a tumor-bearing mouse injected with a 
mixture of AuNP 1, 2, and 3. (a) Optical image of the mouse 
splenic tissue. (b) Representative mass spectrum of the red pulp 
region of the spleen, indicating the existence of AuNP 1, 2, and 3. 
Gold ion (m/z 197) was indicated by a plus sign (+). Ion intensity 
images of (c) AuNP 1 (m/z 436); (d) AuNP 2 (m/z 492); (e) AuNP 
3 (m/z 548); and (f) gold ion (m/z 197) are illustrated. (g) 
Representative mass spectrum of the white pulp region of the 
spleen that shows the detection of AuNP 3. (h) The overlapped 
image of AuNP 1, 2, and 3, indicating the colocalization of the 
three AuNPs. (i) Expanded image of the distribution of AuNPs in 
the white pulp region (scale bar represents 500 μm). (j) Statistical 
evaluation of the surface functionality dictated biodistribution of 
AuNPs in the white pulp areas (one-way ANOVA was performed, 
n = 6, and all error bars represent standard deviation). ***, P < 
0.001; n.s., P > 0.05. ............................................................................. 110 
 xvi 
6.10. LDI-MS images of AuNP 2 in mouse liver tissue. Left: LDI-MS image of 
gold ions; right: LDI-MS image of ligand ion from AuNP 2 (m/z = 
492) (scale bar represents 1 mm). ......................................................... 116 
6.11. H&E staining images of the splenic tissue. (Scale bar = 200 µm). ..................... 117 
6.12. Relative ionization efficiencies of AuNP 1-3. (a) A constant concentration 
of an internal standard AuNP (I.S.) was mixed with different 
concentrations of AuNP 1-3 in cell lysates and then analyzed by 
LDI-MS. (b) The LDI-MS intensity ratios between AuNP 1-3 and 
I.S. were then plotted against the concentrations of AuNP 1-3. The 
resulting slopes for each NP provide a relative measure of their 
ionization efficiency because the same I.S. AuNP is used in each 
case. ....................................................................................................... 117 
6.13. Sensitivity determination of the LDI-MS imaging technique. (a) optical 
microscopy image of the laser burns on a 12 µm thickness splenic 
tissue. Laser stepwidth: 100 µm. Scale bar represents 100 µm. (b) 
laser burn size distribution (100 measurements), size of the laser 
burns: (45 ± 6) µm. ............................................................................... 119 
 
  1 
CHAPTER 1 
INTRODUCTION 
1.1 Nanoparticles and biomedical applications  
The ability to innovate and utilize new materials has been one of the strong forces 
to push human civilization forward in the past thousands of years.
1
  Each revolution in 
materials science has significantly shaped human society and the periods of human 
prehistory have been named using their respective tool-making materials such as stone, 
bronze, and iron.
2
 Artificial nanomaterials actually were used long before they were 
defined as nanomaterials.
3
 Egyptian blue was found to be the first manufactured 
nanomaterial used for decoration purposes as long as 5,000 years ago.
4
 State-of-the-art 
analytical techniques enable the discovery and fine characterization of these ancient 
pigments as well as the innovation of new materials.
4
 The invention of advanced 
analytical techniques such as electron microscopy make it possible to better characterize 
nanomaterials and contribute to the explosive growth of modern nanotechnology.
5
 
Manufactured nanomaterials are currently used in over 1,600 consumer products,
6
 
and nanoparticles (NPs) have attracted more and more interest due to their high surface-
to-volume ratio, tailorable core materials and surface properties.
7,8
 These unique 
properties of NPs open up many biomedical applications,
9,10
 such as drug delivery,
11-13
 
molecular recognition,
14
 sensing,
15
 imaging
16-18
 and therapy.
19-21
 For example, NP-based 
cancer therapeutics have shown the ability to provide higher tumor site specificity, 
efficient cellular uptake and increased payload delivery relative to small molecule 
therapies.
21-23
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Figure 1.1. Various types of NPs have been developed for cancer therapy. Cartoon key: 
(a) polymeric nanogel, (b) polymeric micelle, (c) gold NP (AuNP), (d) iron oxide NP, (e) 
siRNA ensconced in a liposome delivery vector, and (f) a stimuli-responsive capped 
mesoporous silica NP. (Reproduced from Ref. 21) 
 
Monolayer-protected NPs are usually fabricated with a wide range of self-
assembled monolayers (SAMs) of organic compounds. The SAMs are chemisorbed onto 
metal/semiconductor core surfaces to make the NPs stable, soluble in water, 
biocompatible and chemically diverse.
7,24-28
 A summary of some widely used core 
materials, corresponding surface ligands and their applications can be found in Table 
1.1.
24
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Table 1.1. Characteristics, ligands and representative applications for various metal and 
semiconductor materials.  
Core material Characteristics Ligand(s) Applications 
 
Au 
Optical absorption, 
fluorescence and 
fluorescence quenching, 
stability 
Thiol, disulfide, 
phosphine, amine 
Biomolecular 
recognition, delivery, 
sensing 
Ag Surface-enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic property Thiol, phosphine, 
amine, isocyanide 
Bio-catalyst, sensing 
CdSe Luminescence, photo-
stability 
Thiol, phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, amine 
MR imaging and 
biomolecule 
purification 
SiO2 Biocompatibility Alkoxysilane Biocompatible by 
surface coating 
(Reproduced from Ref. 24) 
 
There are a lot more monolayer-protected NPs with a diverse combination of core 
materials (such as metal, alloy, oxide, and semiconductor) and SAMs have been 
fabricated. Figure 1.2 illustrates a schematic summary of the most commonly used 
monolayer-protected NPs in this dissertation.  
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Figure 1.2. Schematic demonstration of monolayer-protected NPs. (a) Schematic 
representation of a 2 nm AuNP with 11-mercaptoundecanoic acid monolayer and relative 
sizes of papain and a 24-mer DNA duplex. (Reproduced from Ref. 24) (b) Design and 
function of the SAMs on NP cores.  
1.2 Characterization of monolayer-protected NPs   
While tremendous progress has been made in nanotechnology since the late 20
th
 
century, the need for better analytical tools to characterize, detect, and quantify 
nanomaterials has arisen significantly. NP characterization is important for accessing 
their physical properties (such as size, shape, and surface chemistry) and quality control 
purposes.   
A wide array of techniques has been used for characterizing general physical 
properties of NPs. Atomic force microscopy (AFM),
29
 transmission electron microscopy 
(TEM),
4,30
 and scanning tunneling microscopy (STM)
31
 are typically used to measure NP 
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core dimensions. However, the SAMs on NPs cannot be characterized using any of the 
above techniques. X-ray diffraction (XRD)
4,32
 and small-angle X-ray scattering 
(SAXS)
33,34
 are also utilized for the characterization of NPs. In another sense, it is very 
challenging for those techniques to provide valuable information about the SAMs. The 
SAM ligands control surface charge and properties of NPs, and it is essential for the 
specific and/or non-specific interactions between NPs and biological molecules.
35-37
 
Thus, new approaches for the characterization of the SAMs are very important.  
The ligand-to-core mass ratios can be obtained by thermogravimetric analysis 
(TGA)
38,39
 and microscale TGA,
40
 but this approach provides almost no structural 
information on the ligands. Nuclear magnetic resonance (NMR) is often chosen as a 
straightforward method for the analysis of AuNPs
7,39
 and quantum dots (QDs).
41
 Even for 
some of the magnetic NPs, the surface ligands can still be characterized by high-
resolution magic-angle spinning (HRMAS) NMR.
42
 However, NMR peaks are 
significantly broadened when attached to magnetic NPs as compared to the resonances of 
the free ligands, which can sometimes complicate peak assignments. Moreover, NMR 
generally requires a large amount of sample for each measurement. Alternatively, UV-
Vis
43
 and Fourier transform infrared spectroscopy (FT-IR)
44
 are capable of providing 
rough identification of surface ligands. However, the ligand atoms close to the core 
cannot be well identified because of the broad signals.  
1.3 Mass spectrometric characterization of NPs   
Mass spectrometry (MS) is a useful tool for characterizing NPs because of the 
universality of this measurement technique. Several MS techniques have been used to 
characterize NPs, including laser desorption/ionization (LDI),
45-49
 matrix-assisted laser 
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desorption/ionization (MALDI),
50,51
 electrospray ionization (ESI),
52,53
 fast atom 
bombardment (FAB),
54 
direct analysis in real time (DART),
55,56
 and ion mobility (IM) 
MS.
57-59
  
LDI-MS was first employed for intact AuNP analysis by Whetten et al. on a 
home-built LDI-TOF mass spectrometer in 1996.
45
 Intact gold clusters (ranging from 
Au116 to Au459) were measured but there was little information about the SAM ligands.  
Schaaff subsequently analyzed AuNPs with LDI-MS and MALDI-MS using both 
positive and negative ion modes. In these experiments, this group found peaks 
corresponding to intact AuNPs at around 29 kDa and [AuxSy] clusters at lower m/z 
ratios.
49
 In the MALDI-MS analysis of AuNPs, peaks at low m/z ratios corresponding to 
alkanethiol ligands or their fragments also can be measured. These studies were limited to 
only certain types of NPs with particular numbers of gold atoms and SAM ligands. 
MALDI-MS has not been successfully applied to detect intact AuNPs with a relatively 
wide range of core sizes until very recently.
50,51
 Therefore, it remains unclear whether 
MALDI-MS is capable of analyzing a wide variety of NPs with different core materials 
and/or surface ligands, especially when the core size and ligand coverage of NPs cannot 
be precisely controlled.   
Intact AuNPs have also been analyzed by other MS techniques, such as ESI,
52,53
 
FAB,
54
 and IM-MS.
57
 Murray and co-workers used FAB,
54
 MALDI,
50,51
 and ESI-MS
60,61
 
to analyze intact gold clusters with 25 gold atoms and 18 organothiolate ligands 
(Au25L18NPs).
52,53
 The intact Au25L18NPs as well as the fragments of the gold core and 
SAMs were then analyzed in detail using IM-MS by Angel et al.
57
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In ESI, the intact gold cores together with organothiolate ligand shells are ionized, 
providing AuNP composition with atomic level detail.
52,53
 It is a powerful tool and 
provides the exact composition of Au25(SCH2CH2Ph)18-x(L)x NPs. It has also been 
applied to a broader range of NPs. For example, Jin and co-workers also reported 
characterization of silver clusters using ESI-MS.
62
 ESI and FAB-MS, however, have only 
been shown to be effective for a rather limited set of NPs with a limited number of core 
metal atoms and certain types of ligands so far.  
IM-MS provides the ligand segregation information and could potentially be a 
great tool to quantify the surface components on the NPs.
59,63,64
 DART-MS focuses on 
the analysis of the surface ligands on the NPs due to the limited m/z range over which it 
can generate ions.
55,56
 However, neither IM nor DART-MS has demonstrated the 
capability to provide the SAM ligand characterization in complex mixtures such as cells 
or tissues due to the lack of the selective ionization ability in the complex biosystems.  
1.4 Detection of NPs   
Sensitive and selective detection and quantification of NPs is critical for 
evaluating the biodistribution and environmental fates of NPs.
65-71
 Tremendous effort 
have been put into monitoring nanomaterials in complex systems such as bacteria,
72
 
worms,
73
 plants,
74
 and animals.
75
  
Considering the complexity of biological systems, the detection of NPs requires 
that the analytical methods have very high tolerance to biomolecules and very good 
selectivity. Using these requirements as a filter, TEM, NMR, TGA, and many techniques 
may not be good candidates to perform the analysis in biological samples. For example, 
the throughput of cellular TEM methods
76
 is extremely low in terms of the number of 
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cells that can be examined at a time, and quantitative information is difficult to obtain. 
Optical methods, such as confocal microscopy
77
 can be employed for characterization of 
NPs in biological systems. However, these techniques require NPs with unique optical 
properties and cannot provide accurate quantitative information. Additional labelling 
steps (e.g., chemiluminescence
78
 or in situ polymerase chain reaction
79
) can facilitate the 
detection of NPs in complex systems, but the labels may change the behaviors of NPs, 
and it is challenging to design numerous labels/reactions for broader applications of these 
approaches.  
Elemental analysis methods such as inductively coupled plasma mass 
spectrometry (ICP-MS)
80
 and atomic absorption spectroscopy (AAS)
81
 are widely used 
for the quantitative analysis of NPs in very complex biosystems. For example, the effect 
of surface chemistry on the uptake and distribution of AuNPs in Japanese medaka fish
82
 
and plants
83
 was investigated using ICP-MS by Zhu. et al. Four plant species (radish, 
ryegrass, pumpkin, and rice) were grown in the presence of AuNPs with positive, 
negative, and neutral surface ligands (Figure 1.3). The gold accumulation amounts in the 
roots and shoots were measured. The quantitative results reveal the uptake efficiencies 
and translocation factors of these AuNPs (Figure 1.3). However, these methods provide 
little information on the SAMs of NPs. This limits the application of these methods for 
the multiplexed screening of NPs with the same core material. We hypothesize a method 
which is able to measure NPs with different functionalities simultaneously can minimize 
the individual variances and thus provide more reliable results for the investigation of the 
surface chemistry effects on NP biodistribution.  
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Figure 1.3. AuNPs uptake by plants after 5-day treatments: AuNP amounts found in the 
roots (a) and shoots (b) of four different plants. The plants were each exposed to 30 nM 
AuNPs (1-3) for 5 days. The means are averaged from at least six replicates, except in the 
case of the pumpkin where only three replicate experiments were conducted. Error bars 
correspond to standard error of the mean. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 from 
unpaired t-tests between the control and AuNP treated groups. (c) Translocation factors 
(TF %, [Au] in shoots/[Au] in KI/I2 etched roots) of AuNPs in different plant species. (d) 
Structural illustrations of the AuNPs used in this study. (Reproduced from Ref. 83) 
 
Mass spectrometric methods are good candidates for the detection of various NPs 
because previous reports of MS-based techniques illustrate multiplexed analyses of a 
broad range of analytes.
84
 Moreover, many MS methods (such as FAB, LDI, ESI, 
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MALDI, IM, and Dart-MS) have demonstrated promising capability for NP 
characterization as described in the previous section. However, it is very different to 
analyze of NPs in complex sample environments compared to the pure NPs. So far, it is 
very challenging for FAB-MS to be applied for the detection and quantification of NPs in 
biological systems due to the hard ionization process.
85
 While neither IM nor DART-MS 
has demonstrated the capability to provide the SAM ligand characterization in complex 
mixtures such as cells or tissues due to the lack of selective ionization, the ESI and 
MALDI conditions to ionize the intact NPs may also ionize the biomolecules and 
introduce significant amount of interference in the mass spectra.
51,61,86
 LDI-MS, on the 
other hand, has shown promising applications in the detection and characterization of 
NPs.
48,87-90
  
1.5 New developments in LDI-MS for the detection of NPs    
LDI-MS detection of NPs in biological systems was first established in 2008.
48
 In 
LDI-MS, a laser irradiates the sample and the NP cores absorb the laser energy.
91,92
 This 
laser energy is then transferred to desorb/ionize the surface ligands. LDI-MS 
characterization of NPs can be performed on a wide range of NPs with various NP core 
materials, because most core materials of monolayer-protected NPs efficiently absorb at 
wavelengths such as 337 and 355 nm, which are the laser wavelengths used on most 
commercial mass spectrometers. For example, surface alkanethiol compounds on AuNPs 
can be detected because the gold core efficiently absorbs the laser energy, and this energy 
is readily transferred to cleave the Au-S bond and desorb/ionize the surface monolayer.
93
  
The localized laser energy transfer from the core materials to the SAM ligands 
allows LDI-MS to have very high selectivity and tolerance to interferences, thus enabling 
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its application in biological systems. For example, Zhu et al. demonstrated the 
multiplexed detection and quantification of AuNPs with different SAM ligands in cell 
lysates.
48
 The relative AuNP amounts taken up by cells were measured by LDI-MS and 
validated by the traditional ICP-MS experiments. This LDI-MS readout was fairly 
specific for monolayers attached to the AuNP and showed few biomolecule interferences.  
 
Figure 1.4. Scheme of LDI-MS characterization process of surface ligands on NPs. 
 
This selective ionization process has also been tested and utilized by other 
researchers for various applications.
94-96
 For example, Nishimura et al. tagged AuNP with 
a functionalized alkanethiol monolayer that was terminated with carbohydrates (e.g. 
GlcNAc), and these monolayers were used as enzyme substrates for a glycosyltransferase 
reaction. Once treated with the proper glycosyltransferase enzyme, the mass change of 
alkanethiol ligands under LDI analysis enabled the rapid and direct detection of the 
enzymatic reaction.
46
 Others have also reported that SAMs on AuNPs can be used for 
signal amplification for the sensitive detection of biometals and biomolecules.
47,97
  Qiu et 
al. designed a DNA hybridization assay, composed of surface bound capture DNA 
strands, to target DNA strands for detection, and probe-strand-capped AuNPs with 
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monolayer “barcodes.” The monolayers can be directly read out by LDI-MS, allowing 
DNA detection with a detection limit of 100 pM.
47
 These applications demonstrate that 
LDI-MS is a very unique technique to characterize the NPs due to its broad universality, 
high selectivity, and most importantly, high tolerance to biological interferences.  
 
1.6 Imaging NPs using LDI-MS    
Monolayer-protected NPs are promising and widely exploited in biotechnology 
and materials science.
7,8,25
 The biomedical applications of NPs and the growing concern 
over environmental exposure to NPs require new tools to examine their potential 
biodistributions.
65-67
   
Site-specific information for nanomaterials is typically obtained using magnetic 
resonance imaging (MRI),
12,98
 Raman spectroscopy,
99-101
 surface plasmon resonance 
(SPR),
29,102,103
 and fluorescence microscopy.
104-106
 These techniques, however, are limited 
to certain types of NPs because they have specific requirements with regard to core 
material or ligand fabrication. Similar limitations also exist in radionuclide-labeling 
methods.
107
  Even though these techniques provide useful insight into NP distributions in 
biological systems, direct quantitative measurements of NPs at local sites is not readily 
achievable for most NPs. In addition, monitoring multiple intact NPs simultaneously, to 
minimize experimental time and enable side-by-side comparisons of different NPs, is not 
easy with existing measurement approaches. Moreover, the readout of existing imaging 
techniques is limited because of the relatively small number of NPs that can be 
simultaneously measured in a single experiment. Therefore, tools that can image multiple 
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NPs at the same time and provide quantitative information about NP distributions, 
regardless of their core material or surface coating, are highly desired.  
A commonly used method for monitoring nanomaterials in biological samples is 
ICP-MS.  This highly sensitive analytical tool can readily quantify metal NPs by 
measuring the total elemental content of the core material. Because atomic species are 
ultimately measured in ICP-MS, NPs in almost any matrix can typically be monitored 
after extensive sample digestion. Sample digestion, however, is time-consuming and 
prevents the simultaneous tracking of multiple NPs. Moreover, site-specific 
biodistribution information is lost during the sample digestion process. It is also 
challenging to confirm whether the nanomaterials are still intact in vivo. 
Mass spectrometric imaging techniques have been very useful for detecting 
peptides,
108
 proteins,
109,110
 lipids,
111
 and other biomolecules
112,113
 in tissues while 
maintaining spatial information. Some preliminary imaging work on NPs has been 
carried out with laser ablation (LA) ICP-MS;
114,115
 however, LA-ICP-MS cannot verify 
whether NPs are still intact because it cannot distinguish between intact NPs and free 
metal ions. Moreover, although LA-ICP-MS has been widely used for imaging metals in 
vitro and in vivo, it cannot provide multiplex detection for the same core material 
nanoparticles.  
I will demonstrate the development of LDI-MS for the investigation of the 
biodistribution of NPs in tissues based on the successful characterization and detection of 
NPs in solutions and cell lysates. LDI-MS imaging has been recently employed for 
monitoring a wide variety of biomolecules such as cancer biomarkers
116
 and lipids.
117
 I 
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will show the development of LDI-MS imaging for monitoring multiple NPs on a simple 
surface and in mouse tissues in this dissertation. 
1.7 Dissertation overview  
LDI-MS has been shown to selectively detect ligands on intact NPs in complex 
biological samples.
48
 This method is based on the selective desorption/ionization process 
of the surface ligands on NPs under the laser irradiation. This method is highly sensitive 
and selective and has provided simultaneous detection of multiple NPs in cell lysates. 
The concept of using “mass barcodes” instead of any other additional labels on NPs 
attracts broad interest to monitor the biological fate of NPs, such as their uptake and 
monolayer stability.
87,88
 In this dissertation, new applications of LDI-MS for the 
characterization, quantification, and imaging of NPs will be described.  
First, I will demonstrate the use of LDI-MS to structurally characterize and 
quantify the surface functionalities of AuNPs in Chapter 2. In this chapter, I will describe 
how LDI-MS can be used to characterize AuNPs with neutral, positively and negatively 
charged surface functional groups. LDI readily desorbs and ionizes the gold-bound 
ligands to produce both free thiols and disulfide ions in pure and complex samples. We 
also find that LDI-MS can provide a quantitative measurement of the ligand composition 
of mixed monolayer AuNPs by monitoring mixed disulfide ions that are formed. The 
quantification results are validated by traditional NMR analysis. The LDI-MS approach 
has several advantages that the NMR methods lack: LDI-MS requires very little sample, 
provides an accurate measure of the surface ligands, and can be used to monitor AuNPs 
in complex mixtures. 
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In Chapter 3, I will further show the capability of LDI-MS for the detection and 
quantification of magnetic NPs where the traditional NMR methods can no longer be 
used for the analysis. In this chapter, functionalized magnetic NPs have been 
characterized by LDI-MS. Quantitative information about surface ligand composition and 
structure for monolayer and mixed monolayer-protected Fe3O4 and FePt NPs can be 
obtained rapidly with very little sample consumption.  
One of the advantages of NPs is the tunability of the surface properties. For 
example, NP-based host-guest chemistry serves as a new controllable platform for drug 
delivery and various other biomedical applications. I will describe a new mass 
spectrometric approach for the characterization and detection of NP host-guest complexes 
in Chapter 4. I will use this simple and fast method to monitor the association and 
dissociation of multiple NP-based host-guest complexes inside the cells. The selective 
trigger of the dissociation process among three nanoparticle-based host-guest interactions 
has been monitored by the new MALDI-MS method. 
Effective use of NPs requires the ability to monitor their spatial distributions for 
biomedical applications and for their potential adverse environmental, health, and safety 
effects. Currently, though, there are limited analytical tools for tracking, quantifying, and 
imaging NPs in biological and environmental systems. In Chapter 5 I will demonstrate 
the use of LDI-MS as an imaging tool to investigate the distribution of NPs. I will show 
the patterns created by the inkjet printing of functionalized AuNPs can be selectively 
detected by LDI-MS imaging. This initial test also demonstrates the feasibility of using 
LDI-MS for the imaging of NPs in biological samples.  
  16 
In Chapter 6, I will further show the application of LDI-MS for monitoring NPs in 
tissues. I will investigate how surface chemistry dictates intra-organ distribution of NPs. 
The described "mass barcode" method minimizes the interference from biomolecules in 
tissues by selectively ionizing the ligands on NPs. This new LDI-MS imaging method 
enables multiplexed imaging with potentially unlimited readouts and without additional 
labeling of the NPs. It provides the capability to detect and image low-attomole level of 
NPs using a commercially available mass spectrometer. Using this new imaging approach 
we find that the intra-organ distributions of same-sized NPs are directly linked to their 
surface functionality. 
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CHAPTER 2 
LASER DESORPTION/IONIZATION MASS SPECTROMETRY ANALYSIS OF 
MONOLAYER PROTECTED GOLD NANOPARTICLES 
2.1 Introduction 
Monolayer protected nanoparticles (NPs) have an inorganic core and a shell of 
organic ligands.
1-4
 The wide variety of available core materials and surface ligands make 
such NPs promising materials for applications in imaging,
4
 molecular recognition,
5
 
sensing,
6
 drug delivery,
3
 and diagnostics.
7
 Depending on the core materials, core-shell 
NPs can be functionalized with different surface ligands (e.g. amine and diol ligands for 
iron oxide NPs, thiol ligands for gold NPs).
3
 These surface ligands protect and stabilize 
NP cores, while at the same time endowing the NPs with unique surface properties. Gold 
NPs (AuNPs) are one of the most widely studied types of NPs. The appeal of AuNPs 
comes from the inherent biocompatibility of gold, the ease with which they can be 
synthesized, and the wide array of functionality that can be added to their surfaces.
2-4
 
Monolayer protected AuNPs are mostly synthesized via the Brust-Schiffrin two-phase 
synthesis method,
8
 and surface functionality can be easily varied via ligand exchange 
reactions first described by Murray and co-workers.
1
 
Effective utilization of monolayer protected AuNPs requires detailed 
characterization of these materials, and a wide array of techniques has been used for this 
purpose. Atomic force microscopy (AFM), transmission electron microscopy (TEM), and 
small-angle X-ray scattering (SAXS) are typically used to measure the size and shape of 
AuNPs.
1,2
 Because surface functionality is a key factor controlling the reactivity and 
properties of NPs, it is also important to characterize ligand populations, especially on 
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AuNPs with mixed monolayers. Several analytical tools are available for characterizing 
the surface ligands on AuNPs. In very special cases, X-ray crystallography can provide 
very detailed structural information of AuNPs, especially the bond connections between 
ligands and the core.
9,10
 This method, however, is not suitable when samples are impure 
or cannot be crystallized,
11
 nor does it allow for rapid analyses. Alternatively, 
1
H-NMR is 
often chosen as a straightforward method for the analysis of AuNPs.
1,12
 Integration of 
specific proton resonances can readily identify ligand populations, but the NMR peaks 
are significantly broadened compared to the resonances of the free ligands, which can 
sometimes complicate peak assignments. Also, NMR generally requires a large amount 
of sample (typically, 1-5 mg) for one measurement. Mass spectrometry (MS) is a 
potentially useful tool for characterizing AuNPs because of the universality of this 
measurement technique. Several MS techniques have been used to characterize AuNPs, 
including electrospray ionization (ESI),
13,14
 matrix-assisted laser desorption/ionization 
(MALDI)
15 
or laser desorption/ionization (LDI),
1,16
 and fast atom bombardment (FAB).
17
 
For example, Schaaff analyzed AuNPs with LDI-MS and MALDI-MS using both 
positive and negative ion modes. In these experiments, he found peaks corresponding to 
intact AuNPs at around 29 kDa and [AuxSy]
-
 clusters at lower m/z ratios.
16
 Murray and 
co-workers subsequently used MALDI
15
 and ESI-MS
13,14
 to determine the exact 
composition of Au25(SCH2CH2Ph)18-x(L)x (Au25) NPs. 
Information on the ligand functional groups that are attached to the gold core is 
complementary to the exact composition of the entire AuNP. For this reason, I have 
begun to investigate the application of LDI-MS to determine ligand identity. LDI-MS has 
been used in the past to directly desorb and ionize self-assembled monolayers (SAMs) 
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from two-dimensional gold surfaces,
18,19
 and a similar result is expected with AuNPs. 
Because the core of AuNPs readily absorbs in the UV region at wavelengths (e.g., 337 
nm and 355 nm) commonly used in commercial mass spectrometers, LDI-MS should 
have the potential to characterize AuNPs with mixed monolayers. Recent work by our 
group
20
 and others
21,22
 indicate that laser energy can be readily transferred to desorb and 
ionize the surface ligands attached to the gold core.  This ionization can be quite selective 
as the surface ligands on AuNPs can be selectively ionized even when present in complex 
matrices such as cell lysate.
20
 
In this Chapter, I investigate the potential of LDI-MS to characterize the surface 
composition of AuNPs. In particular, I am interested in determining the scope of the 
ligands that can be analyzed by this approach. For example, can AuNPs having 
positively-charged, negatively-charged, and neutral ligands be detected by LDI-MS? I am 
also interested in cataloging the ion types that are formed during the LDI-MS process, so 
that the full diagnostic capability of the technique can be realized. Finally, I show that the 
LDI-MS approach can semi-quantitatively assess the ligand composition of mixed 
monolayer AuNPs in a way that (i) requires less sample and is faster than NMR; (ii) is 
more accurate than ESI-MS; and (iii) can be done in complex mixtures in a way that is 
not possible by MALDI-MS. These results have been published in the journal Analytical 
and Bioanalytical Chemistry (2010, 396, 1025-1035).
23
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Figure 2.1. Structural representations of the AuNPs used in this study. 
2.2 Results and discussion 
AuNPs have been chosen to demonstrate the characterization capability of LDI-
MS because of the ease with which they can be synthesized and the increasing number of 
biological and technological applications for which they are being used.
1-4
 The ligands on 
the core-shell NPs have been designed with three sets of functional groups that make 
them stable, soluble in water, and chemically diverse. The alkane-thiol group facilitates 
self-assembly of these NPs onto gold and provides a hydrophobic layer that stabilizes the 
core against disassembly in water. The ethylene glycol group improves the solubility of 
the AuNPs while also preventing non-specific interactions of biomolecules with the 
alkane interiors. Finally, the terminal functional groups allow chemical diversity to be 
built into the NP surface. After synthesis of AuNPs, it is important to characterize the 
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resulting products, especially the ligands that have been attached, and LDI-MS offers a 
simple and flexible way to do this. Below, I demonstrate that LDI-MS can be used to 
characterize a wide variety of mixed monolayer AuNPs by desorbing and ionizing the 
surface ligands of AuNPs (Figure 2.1).   
There are several common ions and fragments observed in the LDI mass spectra 
of the AuNPs. These ions fall into four categories – molecular ions of the thiols, 
fragments of the molecular ions, disulfide ions, and disulfide fragment ions.  
Representative spectra for AuNPs with positively-charged, negatively-charged, and 
neutral surface ligands illustrate these common ions (Figure 2.2). For AuNPs with 
positively-charged ligands, such as AuNP 1, which has the TTMA ligand (Figure 2.2a), a 
molecular ion (MH
+
) is always observed, and in this case it appears at m/z 422. This 
molecular ion can be used to confirm that the intact ligand has been attached to the gold 
core of the AuNP. In most cases, however, the molecular ion is not the most abundant 
species that is observed. Usually, a fragment ion corresponding to a loss of H2S ([MH-
H2S]
+
), m/z 388 for the TTMA ligand, is the most abundant ion, indicating that the laser 
desorption process imparts a significant amount of energy into the desorbed ligands such 
that they can readily dissociate. Further ligand dissociation is also commonly observed in 
the form of ions corresponding to multiple losses of methylene groups from the alkane 
portion of the ligands (Figure 2.2a, labeled as B) and multiple losses from the ethylene 
glycol units as well (Figure 2.2a, labeled as A). 
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Figure 2.2. LDI mass spectra of (a) AuNP 1, (b) AuNP 2 and (c) AuNP 3. In each case, 
M corresponds to the ligand exactly as it is shown in Figure 2.1. The ligand fragment ions 
corresponding to losses of methylene groups are labeled as B, and the ligand fragment 
ions corresponding to losses of ethylene glycol units are labeled as A. The peak in 
spectrum (c) labeled with an asterisk (*) corresponds to tetraoctylammonium (TOAB), 
which is an impurity that remains from the synthesis. In spectra (a) and (c), the small 
peaks corresponding to disulfides with the initial pentanethiol capping group (i.e. 
C5H11S) are only observed when the initial ligand exchange reaction in solution is 
incomplete. 
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Scheme 2.1. Structures of the disulfide ion of AuNP 1 and its two main fragment ions. 
 
At higher m/z ratios, peaks corresponding to disulfide ions are also observed.  If a 
disulfide is formed from the positively-charged TTMA ligand, the expected m/z ratio for 
this doubly-charged ion would be 421; however, no such ion is measured. Instead, an ion 
at m/z 827 is observed, which most likely corresponds to a singly-charged disulfide ion in 
which a methyl cation is lost via a heterolytic bond cleavage from one of the 
tetraalkylammonium groups (Scheme 2.1). Such a loss is somewhat surprising because in 
the gas phase tetraalkylammonium ions more commonly lose alkane radicals upon 
dissociation.
24
 The loss of alkane cations from tetraalkylammonium ions has been 
observed
24
 but are more common for alkyl and dialkylammonium ions.
25,26
 Loss of a 
methyl radical from the disulfide, rather than a methyl cation, would result in an ion at 
m/z 413.8, but no clear evidence for this ion is found in the spectrum. When AuNPs with 
other alkylammonium groups are analyzed, similar disulfide fragments are observed 
without corresponding losses of alkyl radicals. For example, the LDI-MS spectrum of 
AuNP 7 (Figure 2.3), that has two methyl groups and one decyl group attached to the 
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quaternary nitrogen, gives rise to two disulfide fragments in which an alkyl cation is lost. 
The ions at m/z 1079 and 953 correspond to disulfide ions in which methyl and decyl 
cations, respectively, have been lost via heterolytic cleavages. While the reasons why the 
alkyl radical losses are absent in these disulfide ions are intriguing, the investigation of 
this phenomenon is beyond the scope of this study. 
 
 
 
Figure 2.3. (a) Structures of the disulfide ion of AuNP 7 and its two main fragment ions; 
(b) LDI mass spectrum of AuNP 7. 
 
Two other ions, corresponding to losses of 32 Da and 64 Da from the disulfide 
ion, are also sometimes observed in the spectra of positively-charged ligands. For the 
TTMA ligand, these are found at m/z 795 and 763. The exact identity of these ions is not 
known, but the ion at m/z 795 corresponds to a loss of S from the disulfide ion at m/z 827. 
A similar type of ion was also seen in a previous study.
21
 I speculate that this ion perhaps 
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results from a condensation reaction between the (M – H2S)
+
 species and a free thiol, 
which is followed by the loss of a methyl cation (Scheme 1). The ion at m/z 763 could 
correspond to another loss of S (Scheme 2.1) and is more difficult to rationalize, but its 
presence along with m/z 795 suggests that some complex chemistry occurs during the 
desorption/ionization process. 
A close comparison of the region of the mass spectrum around the disulfide ions 
and the free thiol ions shows that the disulfide ions undergo far less fragmentation than 
the free thiol ions. The lower extent of fragmentation likely occurs because the disulfide 
ions have twice as many atoms, and thus the energy deposited from LDI process is 
distributed across more vibrational degrees of freedom, making it less likely to exceed a 
fragmentation threshold.
27
 
In addition to AuNP 1, which has the TTMA ligand, 12 other AuNPs with 
different positively charged ligands were also measured by LDI-MS, and these data are 
summarized in Table 1 of the literature 23. Just as with AuNP 1, LDI-MS of these AuNPs 
resulted in the same four main types of ions—molecular ions of the thiols, fragments of 
the molecular ions, disulfide ions, and disulfide fragment ions. One consistent 
observation is that every AuNPs produces an intact molecular ion (MH
+
), which enables 
confirmation of this ligand’s presence on the AuNP surface. Some ligands, however, are 
more prone to fragmentation than others, and some ligands are more likely to form 
abundant disulfide ions than others. Unfortunately, no clear trend has emerged to predict 
what ligand structural features will lead to more or less fragmentation or disulfide 
formation. 
 
  
Table 2.1. A summary of the dominant ions observed in the LDI mass spectrum of the AuNPs shown in Figure 2.1. 
AuNP 
Ligand Exact 
Mass 
Predominant Ligand Ions in LDI-MHS 
AuNP 1 422.33 
[MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-2]
+
,  
[2M-CH3]
+
, [2M-CH3-S]
+
, [2M-CH3-2S]
+
, [M+C5H11S]
+
, [M+C5H11S-S]
+
 
AuNP 2 381.28 
[MH+Na-H2S]
+
, [MH+Na]
+
, [MH+Na-H2S-(CH2)1-11]
+
, [MH+Na-H2S-(CH2)1-11-(OCH2CH2)1-2]
+
, [2M+Na]
+
, [2M+Na-S]
+
, 
[2M+Na-2S]
+
 
AuNP 3 437.26 
[MH+2Na-H-H2S]
+
, [MH+2Na-H]
+
, [MH+2Na-H-H2S-(CH2)1-11]
+
, [MH+2Na-H-H2S-(CH2) 11-(OCH2CH2)]
+
,  
[2M+3Na]
+
, [2M+3Na-S]
+
, [2MH+Na-CH2COO]
 +
, [2MH+Na-2CH2COO]
+
, [M+C5H11S+2Na-H]
+
, [M+C5H11S+2Na-HS]
+
 
AuNP 4 436.35 
[MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-9, 11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-3]
+
,  
[2M-CH3]
+
, [2M-C2H5]
+
, [2M-CH3-S]
+
, [2M-C2H5-S]
+
, [2M-CH3-2S]
+
, [2M-C2H5-2S]
+
, [M+C5H11S]
+
 
AuNP 5 464.38 
[MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-9, 11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-3]
+
,  
[2M-CH3]
+
, [2M-C4H9]
+
, [2M-CH3-S]
+
, [2M-C4H9-S]
+
, [2M-CH3-2S]
+
, [M+C5H11S]
+
 
AuNP 6 492.41 
[MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-9, 11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-2]
+
,  
[2M-CH3]
+
, [2M-C6H13]
+
, [2M-CH3-S]
+
, [2M-C6H13-S]
+
, [2M-CH3-2S]
+
, [2M-C6H13-2S]
+
, [M+C5H11S]
+
 
AuNP 7 548.47 [MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-7, 11]
+
, [MH-H2S -(CH2)11-(OCH2CH2)1-3]
+
, [2M-CH3]
+
, [2M-C10H21]
+
, [M+C5H11S]
+
 
AuNP 8 490.39 [MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)7, 9]
+
 
AuNP 9 574.49 [MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)4]
+
, [2M-C12H23]
+
 
AuNP 10 566.42 [MH-H2S]
+
, MH
+
 
AuNP 11 484.35 [MH-H2S]
+
, MH
+
, [MH-H2S -(CH2)1, 3-7]
+
, [2M-CH3]
+
, [2M-C6H5]
+
, [M+C5H11S]
+
, 
AuNP 12 498.36 [MH-H2S]
+
, MH
+
 
AuNP 13 466.36 [MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-9, 11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-3]
+
, [M+C5H11S]
+
, [M+C5H11S-S]
+
 
AuNP 14 482.35 
[MH-H2S]
+
, MH
+
, [MH-H2S-(CH2)1-9, 11]
+
, [MH-H2S-(CH2)11-(OCH2CH2)1-2]
+
,  
[2M-CH3]
+
, [2M-C3H7O2]
+
, [2M-CH3-S]
+
, [2M-C3H7O2-S]
+
, [2M-C3H7O2-2S]
+
, [M+C5H11S]
+
 
AuNP 15 465.37 [MH-H2S]
+
, MH
+
, [M+C5H11S]
+
, [M+C5H11]
+
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AuNPs with neutral ligands can also be ionized by LDI-MS, and the mass spectra 
of the neutral ligands are slightly less complicated than the positively-charged ligands. 
For AuNP 2, which has the neutral ligand TEGOH (Figure 2.2b), no molecular ion MH
+
 
(m/z 381) is observed, but a peak corresponding to the sodium adduct [MH+Na]
+
 (m/z 
403) can be seen. As with the positively-charged ligands, fragments corresponding to the 
loss of H2S, multiple methylene groups (Figure 2.2b, labeled as B), and ethylene glycol 
units (Figure 2.2b, labeled as A) are also measured. An abundant disulfide ion is also 
readily observed at m/z 782, which corresponds to the intact disulfide with a sodium 
adduct for charge ([2M+Na
+
]
+
). Occasionally, ions that are 32 and 64 Da lower in mass 
are also observed at m/z 749 and 717; these ions are likely analogous to those shown in 
Scheme 2.1. 
 AuNPs having ligands with negatively-charged functional groups were 
also studied. AuNP 3, which has the negatively-charged ligand TEGCOOH (Figure 2.2c), 
form adducts with two Na
+
 ([MH+2Na-H]
+
). Ions corresponding to losses of H2S 
([MH+2Na-H-H2S]
+
), multiple methylene groups (Figure 2.2c, labeled as B), and 
ethylene glycol units (Figure 2.2c, labeled as A) are also observed, but an additional ion 
at m/z 466, which corresponds to a tetraoctylammonium (TOAB) ion, is also seen. TOAB 
is a phase transfer catalyst that is added during the synthesis of the AuNPs and is 
sometimes observed when the AuNPs are not purified effectively after synthesis.
8
 
Disulfide ions are also observed for AuNP 3, and the molecular composition of the ions 
at m/z 941 and 909 are [2M+3Na-2H]
+
 and [2M+3Na-H2S]
+
, respectively. Occasionally, 
ions at m/z 897 ([2MH+Na]
+
), m/z 839 ([2MH+Na-CH2COO]
+
), and m/z 782 ([2MH+Na-
2CH2COO]
+
) can also be seen. 
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The spectra in Figure 2.2 were all obtained on AuNPs with a single ligand 
attached to the gold core. Mixed monolayer AuNP can also be detected by LDI-MS, and 
distinct ions can be detected in the same spectrum for each ligand. Two examples are 
shown in Figure 2.4. Figure 2.4a shows the spectrum that results when LDI is used to 
ionize AuNPs with a ~17:83 ratio of TTMA to TEGOH ligands. The spectrum has all the 
ions observed in the spectra of the AuNPs with a single TTMA or TEGOH ligand – the 
free thiols of each ligand (m/z 422 for TTMA and m/z 403 for TEGOH), the fragments of 
these thiols, the disulfides (m/z 827 for TTMA and m/z 782 for TEGOH), and the 
fragments of these disulfide ions. A comparable LDI mass spectrum is obtained (Figure 
2.4b) when AuNPs with a mixed monolayer of TEGOH and TEGCOOH (~50:50) are 
analyzed. Again, the spectrum has all the ions observed in the spectrum of the AuNPs 
with the single monolayers. 
The spectra in Figure 2.4a and b also have mixed disulfide peaks, which are 
important for confirming that both ligands coexist on each AuNP. In Figure 2.4a, the 
peak at m/z 801 [(TTMA+TEGOH)
+
] is a disulfide that contains one TTMA chain and 
one TEGOH chain, and in Figure 2.4b the peak at m/z 861 [(TEGOH+TEGCOOH-
H+2Na)
+
] is the disulfide that contains one TEGOH chain and one TEGCOOH chain. 
When individual samples of TTMA AuNPs and TEGOH AuNPs are mixed together so 
that the ligands are not both on the same gold core, the resulting LDI mass spectrum 
(Figure 2.4c) reveals that the mixed disulfide peak is absent. A similar result is obtained 
when individual samples of TEGOH AuNPs and TEGCOOH AuNPs are mixed (Figure 
2.4d). These two results are important because they demonstrate the selectivity of the 
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mixed disulfide ion formation. Mixed disulfide ions only form when two thiols are in 
very close proximity (i.e. on the same AuNP core).  
 
 
 
Figure 2.4. LDI mass spectra of (a) mixed monolayer AuNP with both TTMA and 
TEGOH on the surface (MMNP 1); (b) mixed monolayer AuNP with both TEGOH and 
TEGOH on the surface (MMNP 2); (c) mixture of AuNP 2 (TEGOH ligand) and AuNP 1 
(TTMA ligand); (d) mixture of AuNP 2 (TEGOH ligand) and AuNP 3 (TEGCOOH 
ligand). 
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Another important observation about the spectra in Figures 2.4a and b is that the 
signal intensities of the ligands on the mixed monolayer AuNPs are quite different even 
though the ratios of the ligands are fairly similar. For example, even though the AuNPs 
used to acquire the spectrum in Figure 2.4a have a 17:83 ratio of TTMA to TEGOH, the 
ion abundances for the TTMA-related peaks are significantly higher than those for the 
TEGOH ligands. Two reasons likely explain these differences in ion abundances. First, 
the ionization efficiency of the TTMA ligands is most likely higher than for the TEGOH 
ligands. Second, ionization of the TTMA ligands might suppress the ionization of the 
TEGOH ligand that coexists on the AuNP. 
Despite the different ionization efficiencies of the ligands on a mixed monolayer, 
LDI-MS can still be used to provide a semi-quantitative determination of the relative 
amounts of each ligand. To demonstrate this capability, I used five samples of mixed 
monolayer AuNPs, each differing by the relative percentages of TTMA and TEGOH.  
Mixed monolayer AuNPs with TEGOH percentages of ~10%, 26%, 44%, 68%, and 83%, 
as determined by NMR, were subjected to LDI-MS analysis, and several ion ratios were 
obtained and compared to the known ligand percentages (Figure 2.5). I find that the free 
thiol peaks and their fragments do not provide a good quantitative indication of the ligand 
percentages (Figure 2.5a), but the appropriate ratio of disulfide ions [I801/(I801+I827)] does 
correlate very well with the percentage of the TEGOH ligand (Figure 2.5b).  The 
complex trend with the free thiols might be due to the ease with which these ligands 
fragment. The TTMA and TEGOH ligands have different fragmentation efficiencies, and 
the amount of fragmentation might vary as the ligand percentage changes. Another, more 
likely, explanation may be the source of charge in the TEGOH-related ions. For all the 
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major TEGOH ions (e.g. m/z 403, 369, and 782), sodium is the source of charge, even 
though no excess sodium was added to the sample.  Because no extra sodium is added, 
signals for the free thiols and even the TEGOH disulfide (m/z 782) probably vary from 
sample to sample. Indeed, the ion signals from sodium adducted peaks show quite 
significant run-to-run variability as is evidence by the relatively large error bars for these 
measurements. In contrast, the TTMA signals are relatively stable, and so the mixed 
disulfide peak corresponding to (TTMA+TEGOH)
+
 at m/z 801 provides a stable measure 
of the TEGOH composition, and when ratioed with the total signal from this disulfide ion 
and the TTMA disulfide ion, a very good correlation is observed between ion signals and 
known composition (Figure 2.5c). Such a correlation allows LDI-MS to provide a semi-
quantitative measure of ligand composition from mixed monolayer AuNPs without 
having to resort to more time-consuming (and sample-consuming) NMR experiments. 
Because MALDI-MS has also been used to analyze AuNPs in the past,
15
 I also 
compared our LDI-MS results with a traditional MALDI-MS analysis of these samples. 
Using the same disulfide ion ratio, I find that MALDI-MS ion signals increase with 
increasing TEGOH percentages (Figure 2.5c), but the LDI-MS data provide a better 
correlation. An additional advantage that the LDI-MS approach has is the ability to 
monitor the AuNPs in more complicated samples such as cell lysate (Figure 2.6), which 
is almost impossible by MALDI-MS. In the case of MALDI, the NP ligands are not 
readily observable because of interferences from matrix ions and low molecular weight 
compounds that are present in cell lysate that can be readily ionized in the presence of the 
matrix. 
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Figure 2.5. (a) Comparison of ratios between ions from TTMA ligand and TEGOH 
ligand: I403/(I403+I422) (red line), I369/(I369+I388) (blue line), and 
(I369+I403)/(I403+I422+I369+I388) (black line). (b) Comparison of ratios between disulfide 
ions from TTMA ligand and TEGOH ligand: I782/(I782+I827) (red line), I801/(I801+I782) 
(blue line), and I801/(I801+I827) (black line). (c) Comparison of LDI-MS (red line) and 
MALDI-MS (blue line) for the I801/(I801+I827) ratio. The equation for the LDI-MS fit is, y 
= 1.07x + 0.08, R
2
=0.968. The equation for the MALDI-MS fit is, y = 0.61x + 0.53, 
R
2
=0.817. 
 
 
 
Figure 2.6. LDI mass spectrum of AuNP 1 in cell lysate of cultured monkey kidney cells 
(COS-1). The peak labeled “#” is the molecular ion corresponding to the head-group 
fragment of phosphatidylcholine (m/z 184), which is an abundant lipid in the cell 
membrane of the COS-1 cells.   
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2.3 Conclusions 
In this work, 15 different AuNPs with positively-charged, negatively-charged, and 
neutral ligands were characterized by LDI-MS. Both free thiol and disulfide ions are 
abundantly produced by LDI, and these ions provide a straightforward mean to accurately 
determine the ligand composition on monolayer protected AuNPs. AuNPs with mixed 
monolayers can also be readily detected by LDI-MS, and the resulting disulfide ions can 
be used to provide a semi-quantitative measurement of the ligand composition on these 
mixed monolayer AuNPs. This approach is much faster and less sample intensive than 
NMR, which is commonly used to provide this information. In addition, unlike ESI-MS, 
which is used to measure the entire intact AuNP, the LDI-MS measurements provide a 
more accurate measure of the surface ligand composition because only these species are 
desorbed and ionized. Finally, the ionization selectivity inherent in the LDI process 
means that mixed monolayer AuNPs can be readily analyzed in more complicated 
mixtures. 
2.4 Experimental section 
The reagents necessary for the analysis of the NPs included HPLC grade 
acetonitrile (Fisher Scientific Co LLC, Fair Lawn, NJ), trifluoroacetic acid (Sigma-
Aldrich, St. Louis, MO), and α-cyano-4-hydroxycinnamic acid (α-CHCA). Milli-Q water 
from a Millipore Simpilcity 185 system (Millipore Corp., Billerica, MA) was also used to 
prepare samples. Complete lists of the chemicals used to synthesize AuNPs 1-15 are 
found in the references cited below. 
Synthesis of AuNPs 1-15. The ligands and AuNPs were synthesized using 
methods previously published: AuNP 1, 2, 15;
20
 AuNP 4-12;
28
 AuNP 3;
29
 AuNP 13;
30
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AuNP 14.
31
  In short, the Brust-Schiffrin two-phase synthesis method was first used to 
synthesize pentanethiol-coated AuNPs with core diameters around 2 nm.
8
 Subsequently, 
the Murray place-exchange method was used to functionalize AuNP 1 and AuNPs 3-15. 
AuNP 2 was synthesized by the single phase synthesis method described previously.
20,32
 
NMR analyses. The NMR analyses were done on Bruker Avance400 NMR 
Spectrometer. Approximately 2 mg of the AuNP was dissolved in D2O and analyzed 
using 
1
H-NMR in an identical manner that that described previously.
33,34
 
LDI-MS measurements. The LDI-MS analyses were done either on a Bruker 
Reflex III time-of-flight mass spectrometer (Reflex III) or a Bruker Omniflex time-of-
flight mass spectrometer (Omniflex). Both of the spectrometers are equipped with a 337 
nm nitrogen laser, a 1.0 m flight tube, and a stainless steel sample target. All mass spectra 
were acquired in reflectron mode. Spectra and data in Figure 2.2 and Figures 2.4b and d 
were acquired on Reflex III, using a reflectron voltage of 16.1 kV and an accelerating 
voltage of 20 kV. An average of 50 laser shots was fired to acquire each spectrum on the 
Reflex III, and the typical laser power was 55%. All the other spectra and data were 
acquired on the Omniflex, using a reflectron voltage of 15.9 kV and an accelerating 
voltage of 19 kV. On this instrument, an average of 50 laser shots was fired to acquire 
each spectrum, and a laser power of 50% was used.  
MALDI sample preparation. A saturated α-CHCA stock solution was prepared 
in 70% acetonitrile, 30% H2O, and 0.1% trifluoroacetic acid, and to this stock solution 
was added an equal volume of a 2 μM solution of the AuNP of interest. 1 μL of this 
mixture was applied to target, and after allowing it to dry, the MALDI-MS analysis was 
performed. 
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2.5 Supporting information 
 
 
 
Figure 2.7. TEM imaging of AuNPs: (left) pentanethiol-coated AuNP (the precursor 
AuNP for AuNP 1, 3-15 and MMAuNPs before doing ligands exchange reactions); (right) 
AuNP 2. 
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Figure 2.8. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(10:90). 
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Figure 2.9. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(26:74). 
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Figure 2.10. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(44:56). 
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Figure 2.11. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(68:32). 
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Figure 2.12. NMR spectrum of AuNP with a mixed monolayer of TEGOH and TTMA 
(83:17). 
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CHAPTER 3 
CHARACTERIZATION OF SURFACE LIGANDS ON FUNCTIONALIZED 
MAGNETIC NANOPARTICLES USING LASER DESORPTION/IONIZATION 
MASS SPECTROMETRY 
3.1 Introduction 
Magnetic nanoparticles (MNPs) are used for a wide range of biomedical 
applications
1
 including targeted drug delivery,
2,3
 medical imaging,
4,5
 clinical 
investigations,
6,7
 and materials applications,
8
  including data-storage media.
9
   Successful 
use of MNPs requires surface functionalization to prevent agglomeration and to facilitate 
application in materials and biomedical contexts.
10,11
 Attachment of multiple types of 
ligands, to provide mixed monolayer MNPs, further expands the versatility of these 
particles.
12
    
For any given application, MNPs must be accurately characterized.
12-14
 In 
biomedical applications, the surface ligands dictate the uptake, biodistribution, and even 
toxicity of NPs.
15,16
 These ligands control surface charge and surface properties (e.g., 
hydrophobicity) and thus any specific and/or non-specific interactions MNPs have with 
biological molecules.
17,18
 Surface ligands are also necessary in material applications to 
maintain core magnetism, dispersibility, and stability.
19-21
    
Quantitative characterization of ligand shells on superparamagnetic particles is 
challenging. Nuclear magnetic resonance (NMR) is widely used to characterize non-
magnetic NP surface functionalities,
22
 but ligands on superparamagnetic cores cannot be 
analyzed by traditional NMR. Recently, Polito et al. reported the use of high-resolution 
magic-angle spinning (HRMAS) NMR spectroscopy to characterize the structures of 
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organic molecules attached to MNPs. However, this method lacks sensitivity and is 
difficult to quantify.
23
 Several other techniques, such as X-ray photoelectron 
spectroscopy (XPS),
24
  and Fourier transform infrared spectroscopy (FT-IR),
25
  have been 
used to characterize the surface ligands of MNPs. However, these methods often require 
large amounts of sample, and lack compositional, structural and quantitative information. 
Ion mobility-mass spectrometry (IM-MS) has been recently reported as a means of 
quantifying ligands on gold NPs (AuNPs).
26,27
 Electrospray ionization (ESI) MS and 
matrix-assisted laser desorption/ionization (MALDI) MS have also been used to 
characterize small Au and Ag nanoclusters.
28-31
 However, these MS-based methods are 
limited to homogenous cores with specific amounts of ligands. Moreover, MS methods 
have not been reported for the characterization of intact magnetic NPs.  
Clearly, a general method is required for characterizing the surface functionality 
of MNPs.  Laser desorption/ionization (LDI) MS has shown promise for characterizing 
the surface ligands of AuNPs
21,32,33
 and quantum dots (QDs).
20
  We report here the 
extension of this approach to the quantitative characterization of monolayer and mixed 
monolayer protected MNPs comprised of iron platinum (FePt) and iron oxide (Fe3O4) 
cores (Figure 3.1). This method is broadly applicable and uses widely available MALDI 
mass spectrometers, making it a readily applicable tool for particle characterization and 
quality control. 
In this Chapter, I will show the capability of LDI-MS for the detection and 
quantification of MNPs where the traditional NMR method can no longer be used for the 
analysis. In this chapter, functionalized MNPs have been characterized by LDI-MS. 
Quantitative information about surface ligand composition and structure for monolayer 
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and mixed monolayer-protected Fe3O4 and FePt NPs can be obtained rapidly with very 
little sample consumption. These results have been published in the journal Nanoscale 
(2013, 5, 5063-5066).
34
  
 
 
 
Figure 3.1. Scheme of the structural and quantitative characterization of the ligands 
attached to MNP by LDI-MS. 
3.2 Results and discussion 
We initially tested our LDI-MS strategy using 4.0 ± 0.4 nm FePt NPs synthesized 
according to previous methods (Figure 3.2).
24
 The resulting FePt NPs were functionalized 
with thiol (ligand T) and dopamine (ligand D) anchoring groups. These NPs and NPs 
with similar surface functionalities are being used for biological and material 
applications, where the T and D ligands were engineered to provide stability, 
biocompatibility, water solubility, and different interacting purposes.
24,35
 Varying ratios 
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of the two ligand types were used to generate monolayer and mixed monolayer protected 
FePt NPs (Figure 3.2). 
 
 
Figure 3.2. (a) TEM image of FePt NPs (scale bar = 20 nm). (b) FePt NP size 
distribution (100 FePt NPs), core size of FePt NPs 4.0 ± 0.4 nm. (c) Ligands used for 
FePt NPs. (d) TEM image of Fe3O4 NPs (scale bar = 20 nm). (e) Fe3O4 NP size 
distribution (100 Fe3O4 NPs), core size of Fe3O4 NPs 3.9 ± 0.5 nm. (f) Ligands used for 
Fe3O4 NPs. 
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LDI mass spectra of the three different FePt NPs demonstrate the utility of this 
method for characterizing NPs with ligand T (Figure 3.3a) or D (Figure 3.3b), and NPs 
with mixed monolayers (Figure 3.3c) of T and D. These mass spectra show ions 
corresponding to intact ligands and fragment ions. For the ligand T, with a thiol 
anchoring group, the molecular ion (m/z 422) is of low abundance, while the fragment ion 
(m/z 388) corresponding to the loss of H2S dominates the spectrum (Figure 3.3a).
33
 The 
oxidized product (m/z 436), corresponds to the formation of a carbonyl from a CH2 
group, has also been detected. The 1,2-benzoquinone product (m/z 377) of the ligand D, 
with the dopamine anchoring group is more abundant than the molecular ion, but the 
most abundant ion is the fragment ion at m/z 255, corresponding to the loss of the 
anchoring 4-methylbenzene-1,2-diol group. The identities of the remaining fragment ions 
are shown in the Figure 3.4. When FePt NPs with mixed monolayers were assayed, ions 
from both ligands are readily observed (Figure 3.3c). Significantly, 2 µg of sample and 
less than 2 min is required to obtain ligand structural information for each NP type, 
demonstrating the ready applicability of the method. 
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Figure 3.3. LDI mass spectra of (a) FePt NP with ligand T, (b) FePt NP with ligand D, 
and (c) mixed-monolayer FePt NPs with both T and D. The ligand T fragment ions 
corresponding to the losses of methylene groups are labelled as A, and the ligand T 
fragment ions corresponding to the losses of ethylene glycol units are labelled as B. The 
ligand D fragment ions corresponding to the losses of methylene groups are labelled as C. 
The symbol @ in red (non-italic) corresponds to the ions generated from ligand T while 
the symbol # in blue (italic) indicates ions from ligand D. 
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Figure 3.4. LDI-MS fragmentation pattern of ligand D on the FePt NPs.  
 
The general utility of the LDI-MS method was next demonstrated using Fe3O4 
NPs. The Fe3O4 NPs were synthesized as reported previously
36
 (Figure 3.2) and were 
functionalized by place-exchange reactions using ligands with methyl (ligand M) and 
hexyl (ligand H) end groups. LDI-MS of the resulting NPs indicates that the 1,2-
benzoquinone product (m/z 553) of ligand M and the 1,2-benzoquinone product (m/z 623) 
of ligand H are readily detected (Figure 3.5). The identities of the fragment ions and the 
LDI-MS characterization of Fe3O4 NPs with additional ligands can be found in Figure 
3.6. 
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Figure 3.5. (a) Structures of ligands. (b) LDI mass spectrum of the mixed-monolayer 
Fe3O4 NPs. The m/z ratios in red or marked # correspond to the ions generated from the 
ligand H, while the m/z ratios in blue or marked @ (italic) indicate ions from the ligand 
M. Fragments generated from both ligand H and ligand M are labelled using (!). 
 
 
Figure 3.6. LDI-MS fragmentation pattern of ligand M and ligand H on FePt NPs 
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The above studies demonstrate the use of LDI-MS for qualitative characterization 
of MNPs. LDI-MS can also be used to quantify ligand composition of mixed monolayer 
MNPs. Six mixed-monolayer protected magnetic NPs (NP M1, M2, M3, M4, M5, and 
M6) were prepared with different amounts of ligand T and ligand D. These NPs feature 
various percentage of ligand T and ligand D, and each NP was subjected to LDI-MS 
analysis. Two sets of ions were generated from ligands T and D, and the signal for each 
ligand was determined by summing the ion intensities of all the unique ions for each 
ligand. These ions including the following: for ligand T: m/z = 422, 388, 360, 346, 332, 
318, 304, 290, 234, 218, 190, 174, and 146; for ligand D: m/z = 377, 349, 255, 243, 225, 
198, 170, 156, 142, 128, and 114.   
 
Figure 3.7. LDI-MS analysis of a 1:1 mixture of FePt NPs with ligand D and T. 
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Figure 3.8. LDI-MS and HPLC-MS measurements of surface ligand composition for the 
mixed-monolayer FePt NPs. 
 
Corrections for differences in the ionization efficiencies of the two ligands were 
made by separately analyzing a 1:1 mixture of the NPs with only T and only D (Figure 
3.7). The LDI-MS results were validated by comparing the measured percentages of T 
and D with quantitative HPLC-MS data obtained after dissolving the bimetal core and 
separating/detecting the released ligands by HPLC-MS.
25
 Figure 3.8 shows a plot of the 
ligand T percentage as determined by LDI-MS and HPLC-MS, indicating that 
comparable ligand ratios are obtained with both techniques. It is important to note that 
the LDI-MS sample preparation and analysis for these six magnetic NPs is completed 
within 1 h, while the HPLC-MS analyses require more than 18 h. Representative mass 
spectra of the series of mixed monolayer MNPs can be found in Figure 3.9. 
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Figure 3.9. Representative LDI-MS analysis of mixed monolayer FePt NPs with various 
amount of ligand D (blue, italic) and T (red, non-italic). 
 
3.3 Conclusions 
In conclusion, we have developed a new LDI-MS-based approach for 
characterizing surface ligands attached to MNPs. The method provides structural and 
quantitative compositional characterization of mixed monolayer-protected MNPs. This 
LDI-MS method is simple and fast, and requires very little sample when compared to 
LC-MS or NMR analyses. Numerous samples can be analyzed with minimal sample 
preparation, which is ideal for quality control processes. As we have demonstrated, the 
current LDI-MS method works well for both FePt and Fe3O4 MNPs, and thus represents a 
new tool for MNP characterization and quality control. We predict that the LDI-MS will 
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also be applicable to an even broader range of MNPs, and this will be more fully 
established in the future work. 
3.4 Experimental section 
TEM instrumentation 
JEOL 100 S microscope was used to determine the size of NPs. 
LDI-MS instrumentation 
The LDI-MS analyses were performed on a Bruker Autoflex III MALDI-TOF 
mass spectrometer (Bruker Daltonics, Bremen, Germany) (Autoflex III). The Autoflex III 
is equipped with a Smartbeam 2 laser, and a MTP 384 ground steel sample target. 
Operating conditions were as follows: ion source 1 = 19.00 kV, ion source 2 = 16.60 kV, 
lens voltage = 8.44 kV, reflector voltage = 20.00 kV, reflector voltage 2 = 9.69 kV, 
pulsed ion extraction time = 10 ns, suppression = 100 Da, and positive reflectron mode. 
Laser strength was optimized to around 50 μJ/pulse. Three 2 μL solution samples of each 
NP were applied to target with great care to provide a homogeneous sample area. These 
samples were allowed to air-dry before LDI-MS analyses. Six spectra were collected per 
sample, where each spectrum was obtained at different locations across the target surface.  
ICP-MS Quantification 
Each FePt NP was diluted 100 times using deionized water after place exchange 
reaction and purification. 50 μL of each diluted solution was transferred to 15 mL 
centrifuge tubes. 0.5 mL of aqua regia was added to each sample and then the sample 
was allowed to react for 1 h. Aqua regia is very corrosive and must be treated with great 
caution! The sample solution was then diluted to 10 mL with 1% v/v nitric acid.  
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ICP-MS (Elan 6100, Perkin-Elmer, Shelton, CT, USA) was used to determine the 
195
Pt in 
the NPs. A series of Pt standard solutions (20, 10, 5, 2, 1, 0.5, 0.2, and 0 ppb) were 
measured to build the calibration curve before each experiment. Each sample was 
repeated 3 times, and each replicate was measured 5 times by ICP-MS. ICP-MS 
operating conditions are as follows: rf power: 1600 W; plasma Ar Flow rate: 15 L/min; 
nebulizer Ar flow rate: 0.98 L/min; dwell time: 45 ms. All the magnetic NPs solutions 
were diluted to 10 ug/mL (Pt concentration) for further experiments. 
HPLC-MS Sample preparation 
30 μL of each 30 μg/mL (based on Pt concentration) FePt NP water solution was 
added to 1.5 mL plastic tubes. 30 μL of aqua regia was added to each sample and then 
the sample was allowed to react for 3 h. Aqua regia is highly corrosive and must be 
treated with extreme caution! The sample solution was then neutralized by 60 µL 
ammonium hydroxide (34~36 % v/v) to pH around 7. 10 µL of each neutralized solution 
was subjected to HPLC-ESI-MS analyses. A series of ligand standard solutions (200, 100, 
50, and 20 μM) were prepared following the same procedure described above and 
measured to build the calibration curve before each experiment. Each sample was 
repeated three times. 
HPLC-MS condition 
HPLC separations were performed on an Agilent 1100 (Agilent Technologies, 
Wilmington, DE) HPLC system with a C18 column (15 cm × 2.1 mm, 5 μm particle size, 
Supelco Inc., Bellefonte, PA). The smaller fraction of the LC effluent was fed into the 
mass spectrometer (split ratio of about 1:4).  
A Bruker Esquire-LC (Billerica, MA) quadrupole ion trap mass spectrometer, which is 
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equipped with an electrospray ionization source, was used in this study. All the 
experiments were performed in positive mode, and the electrospray needle voltage was 
kept at 3.5 kV, and the capillary temperature was set to 300 °C. Other operating 
conditions were as follows: nebulizer: 25 psi; dry gas: 10 L/min; skimmer 1: 30.0 V; 
skimmer 2: 6.0 V; cap exit offset: 30.0 V; octopole RF: 195.0 Vpp; lens 1: - 5.0 V; lens 2: 
- 60.0 V; and trap drive: 40.   
 
 
 
 
 
 
 
  65 
3.5 Supporting information 
 
Figure 3.10. Representative LDI mass spectra of Fe3O4 NPs with various amount of 
ligand H and M. The fragmentation patterns can be found in Figure 3.6. Selected 
representative ions have been marked as below: the m/z ratios in red or marked # 
correspond to the ions generated from the ligand H, while the m/z ratios in blue or 
marked @ (italic) indicate ions from the ligand M. Some of the fragments from Ligand H 
and M may overlapped in the mass spectra of mixed monolayer Fe3O4 NPs, and those 
ions are labelled using (!).Some contamination ions generated from the trace amount of 
gold on the sample target have been marked + in the mass spectrum of Fe3O4 NP with 
Ligand M.  
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Figure 3.11. LDI mass spectra of Fe3O4 NPs with other ligands.  
 
 
Table 3.1. HPLC-MS quantification of ligand composition in mixed monolayer magnetic 
FePt NPs 
FePt NPs Ligand T  
(%) 
SD 
(%) 
RSD 
NP M1 42.2 0.7 1.8% 
NP M2 54.3 3.1 5.7% 
NP M3 58.2 4.9 8.4% 
NP M4 64.0 4.9 7.6% 
NP M5 66.2 5.3 8.0% 
NP M6 70.8 6.5 9.2% 
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Table 3.2. 3-day reproducibility of the LDI-MS technique 
FePt NPs 
Day 1 (%) Day 2 (%) Day 3 (%) Reproducibility (%) 
Avg  SD  Avg  SD  Avg  SD  Avg  SD  RSD 
NP M1 45.4 1.6 39.3 2.3 39.8 3.7 41.5 3.4 8.1% 
NP M2 59.2 1.8 57.7 4.6 58.8 0.7 58.5 0.8 1.3% 
NP M3 69.5 11.0 67.6 4.6 64.7 1.5 67.3 2.4 3.6% 
NP M4 79.2 5.9 78.5 5.9 75.3 3.2 77.7 2.1 2.6% 
NP M5 81.7 10.7 81.9 12.6 83.5 4.2 82.4 1.0 1.2% 
NP M6 88.3 11.8 91.6 13.6 88.2 13.9 89.3 1.9 2.1% 
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CHAPTER 4 
MASS SPECTROMETRIC DETECTION OF NANOPARTICLE HOST-GUEST 
INTERACTIONS IN CELLS  
4.1 Introduction 
Host-guest chemistry provides controllable platforms for biomedical applications 
such as cell targeting,
1,2
  biosensing,
3
  imaging,
4
  drug delivery,
5,6
 and cancer 
therapeutics.
7
  The reversibility of the association/dissociation process plays a vital role 
in these applications, allowing host systems to regulate the release of drug guests.
5,6
 
Multifunctional nanomaterials provide particularly versatile scaffolds for these host-guest 
systems due to their biocompatibility and functional versatility.
7,8
 For example, the 
cytotoxicity of gold nanoparticles (AuNPs) can be triggered in cancer cells using 
competitive host-guest binding molecules, providing a new strategy for potential 
therapeutic applications.
7
 
Effective use of nanomaterial-based supramolecular chemistry in biomedical 
applications requires the ability to monitor the association and dissociation of the 
noncovalent conjugates inside cells.
9
  Characterization of host-guest interactions is 
traditionally performed in simple solutions using techniques such as NMR
10,11
 and 
isothermal titration calorimetry (ITC).
12,13
 These methods, however, cannot be used to 
analyze host-guest interactions in biological systems due to the complex environments in 
cells and tissues. Fluorescence spectroscopy is an alternate strategy to detect host-guest 
complexes in complicated biological samples.
14
 This fluorometric method demonstrates a 
new means for the detection of host-guest interactions. The use of florescent probes, 
especially when additional labeling steps are required, can affect the biological behavior 
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of original host-guest complexes due to the alteration of surface properties by the dye.
15
 
Moreover, it is challenging for this method to simultaneously probe multiple host-guest 
complexes.  
Mass spectrometry (MS) is an effective tool for characterizing host-guest 
interactions in solution.
16-18
 For example, electrospray ionization (ESI) MS
17-19
 and 
matrix assisted laser desoption/ionization (MALDI) MS
20,21
 have been utilized for the 
detection of host-guest complexes. However, to the best of our knowledge detecting host-
guest interactions inside cells using mass spectrometry has not been reported, due in large 
part to the large number of interfering ions generated from biological samples.  
In this chapter, I will report here a direct method to monitor the association and 
dissociation of multiple host-guest complexes inside cells (Figure 4.1a). Supramolecular 
complexes formed by the surface ligands of AuNPs and cucurbit[7]uril (CB[7]) serve as 
“mass barcodes” to indicate the presence of AuNP-CB[7] complexes inside cells. This 
method integrates NP-mediated laser desorption ionization (LDI-MS) with MALDI using 
an organic matrix works to selectively desorb/ionize supramolecular complexes of the 
ligands, allowing observation of these species in the presence of other cellular materials. 
Using this method, the intracellular association and dissociation of AuNP-CB[7] 
complexes were monitored, as well as competitive dissociation of these complexes using 
1-adamantylamine (ADA) (Figure 4.1b).  
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Figure 4.1. (a) Schematic illustration of the MALDI-MS detection process of 
supramolecular complexes in cells. (b) Monitoring the selective dissociation of the supra-
molecular complexes after adding the competitive binding molecule ADA. 
4.2 Results and discussion 
We chose the cucurbituril (CB) supramolecular family for our studies. These host-
guest complexes are particularly promising for biomedical applications due to their 
solubility in aqueous media, high affinity and nontoxicity.
22-25
 We probed intracellular 
CB interactions using AuNPs with three types of surface functionalities (Figure 4.2a). 
The AuNP-CB[7] complexes were formed by mixing AuNPs with excess CB[7] (molar 
ratio of AuNP:CB[7] = 1:200). The initial LDI/MALDI-MS detection of the AuNP-
CB[7] host-guest complexes was first in simple aqueous solutions (Figure 4.3). 
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Figure 4.2. (a) Chemical structures of the surface functionalities on the AuNPs used in 
this work. (b) The theoretical mass-to-charge (m/z) ratios of ligands and their 
corresponding supramolecular complexes detected by MALDI-MS. 
The molecular ion of surface ligand L1 on AuNP DAH was readily detected using 
MALDI-MS (Figure 4.3a). The disulfide ion (D1), previously reported in LDI-MS 
analysis of AuNPs
 31
 and the molecular ion (L1) confirmed the presence of AuNP DAH. 
The supramolecular complex ions C1 and DC1 (formed by the D1 ion and CB[7]) 
indicate the detection of the host-guest complexes (Figure 4.3a, see the inset for the 
enlarged region between m/z 1600 and 1800, ion identities are shown in Figure 4.2b). 
This MALDI-MS method for monitoring the AuNP-CB[7] host-guest interactions is able 
to detect the intact supramolecular complexes without generating fragments of the gold 
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clusters
32,33
 or ionizing the intact AuNPs,
34,35
 and thus provides information on the 
ligand-CB[7] interaction.  
 
 
Figure 4.3. Monitoring AuNP-CB[7] interaction in solutions using MALDI-MS. (a) 
AuNP 1-CB[7]. (b) AuNP 2-CB[7]. (c) AuNP 3-CB[7]. 
We applied this method to supramolecular complexes formed by CB[7] and 
AuNPs with different surface functionalities, and analogous mass spectra were acquired 
using AuNP DMAH-CB[7] and AuNP BEN-CB[7] solutions (Figure 4.3b and c). The 
MALDI-MS characterization of the AuNP-CB[7] supramolecular structures can also be 
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applied to NP with a wide range of surface functionalities (Supporting Information, 
Figure 4.7 and 4.8). 
Building on the solution phase experiments, we next explored the ability of this 
method to selectively ionize and detect NP host-guest complexes in cells. HeLa cells 
were incubated with uncomplexed (250 nM) and complexed (250 nM AuNP, 200 
equivalents of CB[7]) and washed with PBS three times to remove the AuNPs and 
AuNP-CB[7] complexes that were not taken up by the cells. After the cells were lysed, 
the resulting samples were transferred to centrifuge tubes, and the pellets containing 
AuNPs or AuNP-CB[7] complexes were collected after the centrifugation (Figure 4.1a). 
We then transferred the pellets to the MALDI-MS sample carrier and applied a thin layer 
of matrix on top of the pellets (Figure 4.1a). Figure 4.4a and 4.4b show typical 
LDI/MALDI mass spectra that are obtained. The surface ligand ions (L1 and D1) are 
observed, indicating the existence of AuNPs in the pellets (Figure 4.4a). The 
supramolecular ions (C1 and DC1) are also readily observed, showing successful 
detection of host-guest complexes inside cells (Figure 4.4b). Interestingly, the relative 
intensities of the complexed and uncomplexed ligands in cells (Figure 4.4b) are different 
than in solution (Figure 4.3a). We are investigating the origins of this disparity. We next 
used LDI/MALDI to monitor the dissociation of host-guest complexes using ADA, a 
strong binding competitor for CB[7]. Since a similar amount of particle was taken up 
with each of the ligands (see Supporting Information Figure 4.9) the same amount of 
ADA was added for each particle. The host-guest complex “mass barcodes,” both C1 and 
DC1 ions, disappear after the cells containing AuNP-CB[7] complexes are treated with 
ADA (Figure 4.4c), indicating the dissociation of supramolecular complexes. Comparing 
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the results in Figure 4.4a and 4.4c, ADA treatment of cells incubated previously with 
AuNP DAH-CB[7] complexes leads to very similar mass spectra as the cells treated with 
only AuNP DAH. Figure 4.4 demonstrates the successful tracking of the association and 
dissociation of AuNP-CB[7] supramolecular complexes in cells by LDI/MALDI-MS. 
 
Figure 4.4 Monitoring AuNP-CB[7] interaction using MALDI-MS. (a) Detection of 
AuNP 1 in cells. (b) Detection of AuNP 1-CB[7] uptaken by the cells. (c) Monitor the 
dissociation of the host-guest complex by adding ADA to the cells containing AuNP 1-
CB[7]. 
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Multiple supramolecular complexes can be followed simultaneously using 
MALDI-MS. This multiplexed detection could provide direct ratiometric measurements, 
significantly reducing the variability introduced from studying different supramolecular 
complexes in separate cell populations. Cells were incubated with three AuNP-CB[7] 
complexes (AuNP DAH-CB[7], AuNP DMAH-CB[7] and AuNP BEN-CB[7]) to 
demonstrate this multiplex capability. Ions corresponding to the surface ligands (L1, L2, 
and L3) of three AuNPs and the host-guest complexes (C1, C2, and C3) are readily 
detected (Figure 4.5a); however, the intensities of the complex ions detected by MALDI-
MS vary due to the different amounts and different ionization efficiencies of the 
supramolecular complexes.   
As above, ADA was used to trigger the dissociation of the AuNP-CB[7] 
complexes inside the cells. In this study, 1.8 μM and 3.6 μM of ADA (total ADA 
amount: 0.9 nmol and 1.8 nmol, respectively) were added to the cells containing AuNP-
CB[7] complexes. We used the intensity ratios of all the supramolecular complex ions (C 
and DC ions) and all the ligand related ions (L, D, C, and DC ions) to evaluate the ADA-
triggered dissociation of the complexes. All the ion intensity ratios were then normalized 
(Figure 4.5b) relative to cells without ADA treatment. The decrease in the normalized ion 
intensity ratios show the dissociation of these three supramolecular complexes are 
different. A more detailed examination using one-way ANOVA reveals that AuNP BEN-
CB[7] complexes are much more stable to ADA treatment than the other two ligands. 
This observation of selectivity illustrates the utility of the of the LDI/MALDI-MS method 
to screen multiple host-guest interactions in cells. 
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Figure 4.5. Monitoring the dissociation of three AuNP-CB[7] complexes in cells. (a) 
Typical mass spectrum of cell samples incubated with a mixture of three AuNP-CB[7] 
complexes. (b) Normalized ion intensity ratios indicating the relative amount of the 
remaining supramolecular complexes after the ADA treatments. n.s., no significant 
difference. **, 0.001<P≤0.01; ***, P≤0.001 through one-way ANOVA (n=9).  
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Figure 4.6. Estimation of the remaining complexes in the cell lysates. 
We have also tested the ability of the MALDI-MS technique for potential 
quantitative analysis of the supramolecular complexes in cells (See Supporting 
Information Table 4.2). The percentage of the remaining AuNP-CB[7] complexes in the 
cells were calculated using the ion intensity ratios obtained in the solution phase as 
references. Since the analytical environments between the cell lysates and solutions are 
very different, Figure 4.6 reflects the trend of the estimated dissociation process of three 
AuNPs. We found that the AuNP-CB[7] complexes dissociated at different degrees prior 
to the ADA treatments (Figure 4c) and AuNP 3-CB[7] showed higher remaining 
percentage. The semi-quantification also illustrates AuNP 3-CB[7] complexes remains 
more when the ADA treatments further dissociated the supramolecular complexes in the 
cells. 
4.3 Conclusions 
In summary, we have demonstrated the use of LDI/MALDI-MS to detect AuNP-
CB[7] complexes in cells, confirming that both formation and dissociation of host-guest 
interactions inside cells can be monitored. This method should be adaptable to in vivo 
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use,
38-40
 with the inherent multiplex capabilities of the mass barcode approach facilitating 
high-throughput approaches. 
4.4 Experimental Section 
Complexation of AuNP 1-3 with CB[7] 
CB[7] solution in deionized water was added into AuNP solution and stirred for 
24 hours. Ratio between CB[7]/NP was kept 200:1. For example, 200uL AuNP 1 solution 
(30 uM) was mixed with 200 uL CB[7] solution (6 mM). 
Cell culture experiment 
60k HeLa cells per well were plated into a 24 well plate 24 hour before the 
experiment. Cells were incubated with AuNP 1, 2, 3-CB[7] complexes (250 nM, 500 uL) 
for 24 hours in DEMEM media containing 10% FBS and 1% antibiotics and then washed 
3 times with PBS( 500uL each washing). Betal Gal lysis buffer (250 uL per well, 5 times 
diluted) was used to lysed the cell. Cell plate was kept under room temperature on a 
vibrator for 30 minutes. For the mixture experiment, AuNP 1, 2, 3-CB[7] complexes 
were prepared in DEMEM media at a concentration of 250 nM for each. Cells were 
incubated with this AuNP-Cb[7] mixture for 24 h and washed 3 times with PBS before 
lysing the cells.  
ADA Treatment 
60k HeLa cells were treated with a single type of NP-CB[7] or a mixture of three 
AuNP-CB[7] for 24 h. Then, they were washed 3 times with PBS (500 uL), and treated 
with ADA at a concentration of 1.8 uM and 3.6 uM for 1 h (total ADA amount: 0.9 nmol 
and 1.8 nmol, respectively). After that, cells were washed 3 times with PBS and lysed 
with Beta Gal lysis buffer. 
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Cell sample preparation 
The cell lysate samples were transferred from the 24-well cell culture plate to 1.5 
ml centrifuge tubes. Then, they were centrifuged at 14000 rpm for 30 min. The pellets 
were transferred to the stainless steel MALDI-MS sample carrier. 2.5 uL of the matrix 
solution was applied on top of each pellet.  
MALDI-MS instrumentation  
MALDI-MS experiments were carried out on a Bruker Autoflex III MALDI-TOF 
mass spectrometer (Bruker Daltonics, Bremen, Germany), equipped with a Smartbeam 2 
Nd:YAG laser.  MALDI-MS operating conditions were as follows: ion source 1 = 19.00 
kV, ion source 2 = 16.60 kV, lens voltage = 8.44 kV, reflector voltage = 20.00 kV, 
reflector voltage 2 = 9.69 kV, and positive reflectron mode in a mass range of m/z 
400−3000. A total of 200 laser shots were fired per measurement. The laser energy has 
been optimized to ~ 40 µJ/pulse. A saturated matrix α-cyano-4-hydroxycinnamic acid (α-
CHCA) solution was prepared in 70% acetonitrile, 30% H2O solution for the MALDI-
MS analysis. 
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4.5 Supporting Information 
 
Figure 4.7. Various AuNPs which bind CB[7] that have been successfully characterized 
by MALDI-MS. The ones in the red box have been utilized for the selective dissociation 
study.  
 
  83  
 
Figure 4.8. Mass spectra of the AuNP-CB[7] complexes. (a) AuNP 4-CB[7]. (b) AuNP 
5-CB[7]. (c) AuNP 6-CB[7]. (d) AuNP 7-CB[7].  
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Figure 4.9. Cellular uptake amount per well of AuNP-CB[7] complexes measured by 
ICP-MS.  
 
 
Figure 4.10. TEM image of pentanethiol (C5) coated AuNPs.  
 
Table 4.1. Detail p values for the comparison between different NP-CB[7] complexes.  
 
p value 0.9 nmol ADA 1.8 nmol ADA 
AuNP 1 vs. AuNP 2 0.7330 0.2207 
AuNP 1 vs. AuNP 3 0.0001 0.0019 
AuNP 2 vs. AuNP 3 0.0002 0.0005 
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Table 4.2. Ion intensity ratios of AuNP-CB[7] complexes in solutions using MALDI-MS.  
Ion Intensity 
Ratio Average SD  
AuNP 1 - CB[7] 0.76 0.08 
AuNP 2 - CB[7] 0.41 0.08 
AuNP 3 - CB[7] 0.025 0.010 
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CHAPTER 5 
LASER DESORPTION IONIZATION MASS SPECTROMETRIC IMAGING OF 
MASS BARCODED GOLD NANOPARTICLES  
5.1 Introduction 
Counterfeit materials are a rapidly increasing global issue.  It is estimated that 
illegally produced materials cost between 5 and 7% of the total annual revenue of 
governments and businesses.
1
  More troubling is the prevalence of fraudulent drugs and 
vaccines that endanger human health, as up to 25% of all drugs available in developing 
countries are counterfeit.
2
 These threats are exacerbated by technological advances in 
image capturing and printing techniques that give criminals new tools to produce high 
quality copies of currency, drug packaging, and security documents.   
While overt protection strategies based on physical or visual inspection remain an 
important part of verifying authenticity, covert methods using specialized materials and 
detection schemes have been devised for high value goods including currency
3
 and 
pharmaceuticals.
4
  Forensic methods requiring laboratory analysis for authentication are 
of particular interest, as the overall complexity of observation serves as a counterfeiting 
deterrent.  Destructive chemical analysis of the material by thin layer chromatography,
5,6
 
liquid chromatography,
7
 and gas chromatography
8
 can identify the inks and pigments 
used in the material; these methods are however unattractive when sample preservation is 
needed.  Furthermore, the solvent needed for analysis can often alter the integrity of the 
response, providing unreliable results.  Ambient, non-destructive analysis techniques 
such as infrared reflectance,
9
 microscope attenuated total reflectance infrared (ATR-IR) 
spectroscopy,
10
 and Raman spectroscopy
11
 have been used to verify authenticity, 
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although the broader use of these methods is limited due to the lack of specific chemical 
information, limiting the output diversity. 
Imaging mass spectrometry (IMS) has recently been used in security applications 
since it produces non-destructive visual representations of mass profiles that can be 
compared to samples known to be genuine.
12-14
 For example, Cooke et al. used ambient 
IMS to analyze valid currencies against known counterfeit bills by ink analysis as a 
proof-of-concept verification technique.
15
 However, the use of solvent complicates the 
analysis procedure.  Designing an ink system that can be directly read by IMS provides 
multiple benefits as the manufacturer can imprint a specific chemical signature viewable 
only through IMS.     
In this Chapter, I will demonstrate that that functionalized gold nanoparticles 
(NPs) can be engineered for accurate detection by laser desorption/ionization MS (LDI-
MS). Recent work by our groups has shown that surface ligands attached to AuNPs 
(AuNPs) can be efficiently ionized due to the particle’s strong absorbance at wavelengths 
(e.g. 337 nm and 355 nm) commonly used in commercially available mass 
spectrometers.
16,17
 We report here the use of surface ligands with unique structures and 
mass fingerprints as “mass barcodes” to identify AuNPs.  These ligands can be altered 
through a wide range of synthetic means, providing flexible and tunable masses for 
detection by LDI-IMS.  Moreover, different ligands can be employed to provide multiple 
channels for higher security as well as higher density of information reporting. In these 
studies, AuNPs were patterned onto a surface by inkjet printing. The correct pattern was 
visible only when the surface was scanned for the correct mass signature of the AuNPs. 
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This study has been published in the journal Chemical Communications (2012, 48, 4543-
4545) and featured as the cover of that issue.
18
  
5.2 Results and discussion 
The ligands for our study were chosen to achieve distinct mass fragmentation 
signals. The ligands featured a thiol bonding group for the gold nanoparticles, an alkane 
chain to stabilize the ligand shell, an oligo(ethylene) glycol to aid water solubility, and a 
variable ammonium group with a flexible mass head group to provide distinctive mass 
signatures.  The chemical structures of the particles and the corresponding MS spectra are 
shown in Figure 5.2.  AuNPs synthesis, place exchange, and inkjet ink formulation can be 
found in the Supporting information.   
 
 
Figure 5.1. Schematic illustration of the anti-counterfeiting inkjet printing strategy used 
in this work. 
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Figure 5.2. Mass spectra of the four nanoparticles used in this study, with the m/z value 
used for scanning highlighted. 
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To validate our system, we first deposited AuNP 1 onto indium tin oxide (ITO) 
coated glass slides, commonly used in IMS.
13,19
 The ions from the gold core as well as 
ions from the surface ligands were successfully detected. In Figure 5.3a, we show the 
successful patterning of our gold nanoparticle inks as the specified pattern can be seen 
when analyzed for the Au
+
 signal.  Scanning for both the Au2
+
 signal and the AuNP 1 
ligand also provided the correct image as seen in Figures 5.3b and 5.3c, respectively. 
 
 
 
Figure 5.3. (a) The Au
+
 distribution determined by scanning the ITO coated glass 
surface. (b)  The Au2
+
 distribution determined by scanning the ITO coated glass surface. 
(c) The signal distribution of the ligand on AuNP 1 determined by scanning the ITO 
coated glass. (Detected ions: Au
+
 m/z = 197, Au2
+
 m/z = 394, AuNP 1 ligand m/z = 422).   
 
To further investigate the capability of this inkjet printing technique, we printed 
separate inks in one printing cycle. A commercially available nano assisted laser 
desorption/ionization (NALDI
TM
) surface was employed in the following experiments.
20-
22
 For our study, we deposited four different AuNP inks onto the NALDI substrate to 
investigate their use as an anti-counterfeiting technique.  Figure 5.4a shows a LDI-IMS 
searching for just the mass barcode for AuNP 1, indicating no visible response from the 
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other printed AuNP inks.  Figures 5.4b-d also show minimal response from the other 
mass barcodes, however, combining all of these scans provides us with the image of 
interest (Figure 5.4e).  This image can only be obtained by analyzing for each of the four 
mass barcodes, greatly reducing the ability of the counterfeiter to visualize the image. 
Since the pattern above could in theory be determined simply by scanning for Au
+
 
or Au2
+
, we printed two different patterns superimposed on each other on the same 
NALDI substrate area.  In Figure 5.5a, we saw no significant visible pattern on the 
substrate.  However, when scanning for the AuNP 1 ligand (m/z = 422), a clear pattern is 
detected on the surface.  When scanning for the AuNP 4 ligand (Figure 5.5c), we saw the 
second pattern on the substrate that was not previously visible.  This demonstrates the 
ability of inkjet printing to deposit multiple nanoparticle patterns onto the same portion of 
a substrate, providing unique and sophisticated mass signatures.  
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Figure 5.4. LDI-IMS images for the various ligands tinted different colors for viewing. 
(a) AuNP 1, (b) AuNP 3, (c) AuNP 2, and (d) AuNP 4. (e) All 4 signals combined 
showing the completed pattern. 
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Figure 5.5. Overlapped two channel printing. MSI of overlapped printing AuNPs, 
detected ions: blue letters AMHERST (AuNP 4 m/z = 548), green letters UMASS (AuNP 
1 m/z = 422), red pattern (Au
+
 m/z = 197). 
5.3 Conclusions 
In this work, we have developed an efficient security strategy using the mass 
signature barcode of functionalized gold nanoparticles to provide discernible patterns 
through LDI-IMS.  By using inkjet printing, we can create surfaces that can be quickly 
altered either by modifying the physical pattern or by changing the functional AuNPs 
used.  The diversity of mass options coupled with the efficiency of the “read” process 
makes this strategy promising for a wide variety of covert anti-counterfeiting 
applications. 
  96  
5.4 Experimental section 
Synthesis of AuNPs 1-4  
Gold nanoparticles with the attached ligand were synthesized in a two-step 
method.  Included in this method was the preparation of pentanethiol stabilized 
nanoparticles of approximate 2.5 nm size using the Brust method followed by a ligand 
exchange reaction.
23
 Ligands were synthesized according to previous methods.
24
 After 
purification, the nanoparticles were diluted to 1µM, filtered through a 0.2µm 
polypropylene membrane (Puradisc 25AS, Whatman), and syringe filtered into a virgin 
aftermarket Epson inkjet cartridge for printing. 
LDI-MS imaging instrumentation 
The LDI-MS image analysis was carried out on a Bruker Autoflex III MALDI-
TOF mass spectrometer (Bruker Daltonics, Bremen, Germany) (Autoflex III). The 
Autoflex III is equipped with a Smartbeam-laser and with the FlexImaging 2.1 software 
package (Bruker Daltonics, Bremen, Germany). LDI measurements were done in 
operating conditions as follows: ion source 1 = 19.00 kV, ion source 2 = 16.60 kV, lens 
voltage = 8.44 kV, reflector voltage = 20.00 kV, reflector voltage 2 = 9.69 kV, pulsed ion 
extraction time = 10 ns, suppression = 180 Da, and positive reflectron mode in a mass 
range of 100−1200 Da. The mass spectrometric imaging sequence was generated by 
FlexImaging 2.1 software. Imaging was performed by continuously scanning the surface 
in the x-direction and y-direction. The lateral resolution for the LDI-MS imaging was set 
to 50 μm. A total of 50 laser shots were measured per position. In general, ~ 400,000 
laser shots were fired in a ~ 20 mm
2
 area. The data analysis and image generation were 
performed in FlexImaging 2.1. The ITO glass slides and the NALDI
TM
 substrate were 
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obtained from Bruker Daltonics (Billerica, MA USA) and Nanosys (Palo Alto, CA USA) 
respectively.  
5.5 Supporting information 
Printing was done using an Epson Artisan 50 inkjet printer (Long Beach, CA 
USA) which was used as packaged. Samples were loaded into the printer by taping the 
bottom of the substrate to the included CD tray. For our work, patterning was done by 
using the Print CD software provided with the Epson printer. The text was written in 
Arial font in Bold at a font size of 2 for appropriate detection. In order to print only the 
channel of interest, the color of the letter has to match the channel printed. To print only 
the magenta channel, the RGB value must be set to (255, 0, 255). To print cyan, the RGB 
value must be set to (0, 255, 255) and to access the yellow channel, the RGB value must 
be set to (255, 255, 0). A representative screen capture of the printed is shown in Figure 
5.6.  The ICM color management also must be turned off in the Advanced tab of the 
printer properties to ensure no mixing of the channels occurs. Before printing, the 
printheads were cleaned two times using the “Head Cleaning” function in the 
Maintenance tab of the printer properties to ensure that the channels were filled. 
 
Figure 5.6. Screen capture of the pattern to be printed on the substrate.  
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Figure 5.7. A LDI-MS image of the logo of the NSF Center for Hierarchical 
Manufacturing printed using AuNPs.  
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CHAPTER 6 
MULTIPLEXED IMAGING OF NANOPARTICLES IN TISSUES USING LASER 
DESORPTION/IONIZATION MASS SPECTROMETRY 
6.1 Introduction 
Various nanoparticles (NPs) with tailorable surface chemistry are widely 
employed in biomedical applications such as drug delivery,
1,2
 sensing,
3
 and 
therapeutics.
4-7
 For these applications NPs are functionalized with different core materials 
and hydrophilic monolayers to provide biocompatibility,
8
 biomolecular targeting,
9
 and 
recognition.
10
 The surface chemistry of NPs plays an important role in the absorption, 
distribution, metabolism, excretion, and toxicity of NPs.
11,12
 For example, Arvizo et al. 
showed that the biodistributions and pharmacokinetics of NPs are dictated by the charged 
character of the monolayers on the NPs.
13
  
The effective use of NPs requires imaging of NPs in tissues, especially in 
biomedical applications.
14,15
 Various approaches (such as optical, electrical, radioactive, 
or magnetic measurements) have been developed for imaging NPs;
16-19
 however, 
multiplexed applications of these strategies are limited because it is challenging to 
engineer the large variety of labels necessary for multiplexed imaging of NPs. Quantum 
dots (QDs) have been used for multiplexed optical imaging;
20
 however, this approach has 
limitations due to QD toxicity.
21
 Additionally, the required variation of core size to tune 
emission maxima affects the biological behavior
6
 of the QDs, a complicating factor in 
assessing their interactions in vivo.
12
 Surface-enhanced Raman scattering (SERS) from 
NPs is another imaging modality that has been used to achieve multiplexed imaging.
22
 
However, for SERS it is challenging to decrease the size of the NPs (typically around 25-
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100 nm) enough to minimize reticuloendothelial uptake.
23
 Therefore, more broadly 
applicable techniques are needed to provide simultaneous site-specific information about 
multiple same-sized and differently functionalized NPs in biological systems.  
Laser desorption/ionization mass spectrometry (LDI-MS) provides an 
advantageous means for multiplexed detection of NPs in complex media, e.g., it has been 
employed to quickly screen multiple NPs in cells.
24
 Specifically, it tracks NPs by 
measuring their surface ligands, which typically control their chemistry in vivo. The NP 
cores absorb the laser energy, which selectively ionizes attached ligands and provides 
highly sensitive detection of NPs. In this method, the ligands that comprise the surface 
monolayer act as “mass barcodes”, enabling simultaneous detection of multiple NPs with 
various core sizes and materials.
24-28
 The cellular uptake of multiple NPs and NP stability 
in cells can both be quantified using this technique.
26,29
  
In this Chapter, I will demonstrate LDI-MS in an imaging format and use this 
powerful new approach to study how surface chemistry dictates NP biodistributions in 
vivo. Using LDI-MS in this format provides a highly sensitive and selective approach for 
the simultaneous imaging of different NPs varying only in surface ligand structure in 
tissues (Scheme 1). This "mass barcode" method minimizes the interference signals from 
biomolecules in tissues by selectively ionizing the ligands on NPs, and images NPs at 
attomole level. The value of this approach is illustrated by multiplexed imaging of gold 
NPs (AuNPs) in mice to allow direct observation of the different intra-organ NP 
biodistributions dictated by NP surface functionality. These results have been published 
in the Journal of the American Chemical Society. (2013, 135, 12564-12567).
30
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Figure 6.1. Workflow for the LDI-MS imaging strategy to obtain the biodistributions of 
multiple AuNPs in mouse tissues. 
6.2 Results and discussion 
 
 
Figure 6.2. Structures of the surface monolayers on the AuNPs used in this study: the 
“mass barcode” is the m/z of the AuNP surface ligand. 
 
We chose three AuNPs for this study, focusing on gold cores due to their promise 
in therapeutic/imaging applications (Figure 6.2).
1
 The specific NPs chosen feature similar 
core diameters ((2.0 ± 0.2) nm, see Figure 6.3). The NPs were functionalized with 
different ligands to both alter their surface properties
12
 and to give the AuNPs unique 
mass barcodes for detection by LDI-MS
25
 (Figure 6.4). Such similar-sized NPs would be 
difficult or impossible to distinguish in tissues by using other methods described 
above.
20,22
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Figure 6.3. Characterization of AuNP 1-3. TEM images of the AuNPs after the Murray 
place-exchange reactions: (a) AuNP 1; (b) AuNP 2; and (c) AuNP 3. Core size 
distribution of each AuNP: (d) AuNP 1; (e) AuNP 2; and (f) AuNP 3 (120 NPs were 
randomly selected). (g) One-way ANOVA test indicates the same core size of these 
AuNPs (n = 120). (h) Overall size distribution of three AuNPs (360 NPs). The 
hydrodynamic size of each AuNP was measured by dynamic light scattering (DLS): (i) 
AuNP 1; (j) AuNP 2; and (k) AuNP 3. Zeta-potential measurements of the AuNPs are 
shown in panel (l) AuNP 1; (m) AuNP 2; and (n) AuNP 3. 
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Figure 6.4. LDI-MS characterization of (a) AuNP 1; (b) AuNP 2, and (c) AuNP 3. The 
LDI-MS results are consistent with previous research.
24,25,27
 Symbol key: +, Au
+
 (m/z 
197); ++, Au2
+
 (m/z 394); +++, Au3
+
 (m/z 591); MH
+
, the molecular ion corresponding to 
surface ligand; A, a fragment ion corresponding to a loss of H2S ([MH-H2S]
+
) from the 
intact ligand; B, ions corresponding to multiple losses of methylene groups from the 
alkane portion of the ligands; C, ions corresponding to multiple losses of ethylene glycol 
groups from the ligands. 
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For the imaging studies, AuNP solutions were intravenously injected into mice 
that were then sacrificed 24 h after NP administration. The amount of gold in major 
organs was quantified by using inductively coupled plasma (ICP)-MS (Figure 6.5), and 
these measurements showed that the AuNPs accumulated to the greatest degree in the 
liver and spleen, as expected.8 For our study, the splenic tissues were chosen because 
they have distinct histological regions (i.e., red pulp and white pulp)
31
 that allow us to 
compare these regions in optical images and LDI-MS images side-by-side. 
 
 
Figure 6.5. AuNP amounts in different organs as determined by ICP-MS. The AuNP 
concentrations were calculated by the gold amount (ng) divided by organ weight (g) (± 
standard error of the mean). (control group: n = 3, experimental group: n = 4). 
 
Splenic tissue samples harvested from the mice were embedded, sliced, and 
placed on an indium tin oxide (ITO) coated glass slide for LDI-MS detection. The “mass 
bar-codes” of injected AuNPs and ions from the gold core (m/z 197) were detected by 
LDI-MS (Figure 6.6a, b, and c), indicating the existence of the AuNPs in the tissues 24 h 
after intravenous administration. 
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Figure 6.6. Representative LDI mass spectra of AuNPs in mouse spleen. (a) AuNP 1 
(molecular ion m/z = 436). (b) AuNP 2 (molecular ion m/z = 492). (c) AuNP 3 (molecular 
ion m/z = 548). Other ions in the spectra correspond to fragments of the 
phosphatidylcholine head groups (m/z 184, 202, and 230), which are indicated with *, 
and Au
+
 (m/z 197), which is indicated by a +. 
Very few ions from the multitude of bio-molecules found in tissues are observed 
in the mass spectra due to the absence of an applied matrix, a selectivity atypical for 
matrix assisted laser desorption/ionization (MALDI) MS imaging.
32
 Because only the NP 
cores absorb the specific wavelength of laser light used (i.e., 355 nm), selective 
ionization of the ligands occurs. The selective detection of only ligands bound to the 
AuNPs and not free ligands or other isobaric ions was confirmed by a series of control 
experiments (see Figure 6.7 for the LDI-MS analysis of a posthoc mixture of free ligand 
and mouse tissues). 
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Figure 6.7. LDI-MS on spleen tissue from mouse injected with DPBS buffer. Control 
experiments to confirm that the “mass barcodes” of AuNPs are only observed when the 
ligands are attached on the gold cores. (a) Typical LDI mass spectrum of spleen tissues 
from a mouse that was not injected with AuNPs. (b) Typical LDI mass spectrum of a 
tissue slice from a non-injected mouse that was spiked with free ligands (1 μL of 5 μM 
ligand mixture solution). (c) Example LDI mass spectrum of a spleen slice from a non-
injected mouse that was spiked with 1 μL of a 50 nM mixture of AuNP 1, AuNP 2, and 
AuNP 3. Symbol key: *, ions from phosphatidylcholine head groups; +, gold ions; #, 
interference ions from the ITO glass slide; F1 and F2, fragment ions corresponding to a 
loss of H2S ([MH-H2S]
+
) from molecular ions of ligands on AuNP 1 and 2, respectively. 
 
We next explored the imaging capability of LDI-MS. In this process, the laser 
beam was rastered across tissue sections, and the ion intensities of selected m/z were used 
to generate an ion intensity map that is indicative of AuNP distribution within the tissue. 
Figure 6.8 a, b, and c are LDI-MS images of AuNP 1, 2, and 3, respectively. These 
images clearly show that the functionalized AuNPs accumulate in the red pulp region of 
the splenic tissues, confirming that the vascular red pulp areas eliminate these AuNPs 
from circulation in the mouse.
33
 Importantly, we find attomole levels of AuNPs can be 
routinely detected (see Supporting information for details), allowing use of a significantly 
lower dose of NPs in the in vivo experiments than is required by other imaging methods.  
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Figure 6.8. LDI-MS images of AuNPs in mouse spleens. The biodistributions of AuNPs 
are shown in panel (a) AuNP 1, (b) AuNP 2, and (c) AuNP 3. Ions selected for image 
generation: AuNP 1 m/z 436, AuNP 2 m/z 492, and AuNP 3 m/z 548. Scale bar represents 
500 µm. 
 
To demonstrate multiplexed imaging, three different AuNPs were concurrently 
injected into a tumor-bearing mouse. In this experiment, 24 h after the injection, the 
organs were collected, sliced, and imaged. LDI-MS images of selected tissues from a 
mouse injected with AuNPs 1, 2, and 3 are shown in Figure 6.9. The optical image 
illustrates the regions of the spleen (Figure 6.9a; see the Supporting Information Figure 
6.10 for hematoxylin and eosin staining image). Gold and surface ligand ions from each 
AuNP were readily detected (Figure 6.9b); this confirms the multiplexed imaging 
capability of our approach.  
  110  
 
 
Figure 6.9. LDI-MS images of spleens from a tumor-bearing mouse injected with a 
mixture of AuNP 1, 2, and 3. (a) Optical image of the mouse splenic tissue. (b) 
Representative mass spectrum of the red pulp region of the spleen, indicating the 
existence of AuNP 1, 2, and 3. Gold ion (m/z 197) was indicated by a plus sign (+). Ion 
intensity images of (c) AuNP 1 (m/z 436); (d) AuNP 2 (m/z 492); (e) AuNP 3 (m/z 548); 
and (f) gold ion (m/z 197) are illustrated. (g) Representative mass spectrum of the white 
pulp region of the spleen that shows the detection of AuNP 3. (h) The overlapped image 
of AuNP 1, 2, and 3, indicating the colocalization of the three AuNPs. (i) Expanded 
image of the distribution of AuNPs in the white pulp region (scale bar represents 500 
μm). (j) Statistical evaluation of the surface functionality dictated biodistribution of 
AuNPs in the white pulp areas (one-way ANOVA was performed, n = 6, and all error 
bars represent standard deviation). ***, P < 0.001; n.s., P > 0.05. 
Given the role of spleen in the immune system, the fact that it is enlarged when 
tumors are present, and its response to the surface chemistry of AuNPs,
34
 we closely 
examined the LDI-MS images of this organ. These images indicate that gold and surface 
ligand ions were detected mostly in the red pulp region of the spleen (Figure 6.9c, d, e, 
and f). The pre-dominance of the AuNPs in the red pulp is due to the role of the spleen in 
blood filtration and clearance. Significantly, intact AuNPs can also be detected in the 
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white pulp region of the spleen (Figure 6.9g and h) that contains lymphocytes that are 
involved in immune responses. An expanded image of one region of the white pulp 
shows that AuNP 3, with the most hydrophobic monolayer, accumulates to a significantly 
greater extent in this region than the other two AuNPs (Figure 6.9i). Statistical evaluation 
of the average mass spectrometric intensity per pixel shows that AuNP 3 accumulates to a 
greater extent than the other two AuNPs in the white pulp (Figure 6.9j). When we further 
consider that the relative ionization efficiency of AuNP 3 is very similar to AuNP 1 and 
lower than AuNP 2 (Figure 6.12 in the Supporting information), then it becomes even 
clearer that the AuNP 3 is accumulated more significantly in the white pulp region. These 
data indicate that the intraorgan distribution of the NPs is influenced by the surface 
chemistry of the specific NP. This information is difficult to show by traditional 
techniques, highlighting the advantage of multiplexed LDI-MS imaging. 
 
6.3 Conclusions 
In summary, the surface chemistry dependent intraorgan distributions of NPs have 
been investigated by a new MS-based imaging technique. The LDI-MS imaging method 
enables the detection of multiple NPs at attomole levels in tissues. Because our approach 
uses NP surface-ligand mass as the readout, a very large number of NPs can potentially 
be simultaneously imaged, resulting in a significant multiplexed advantage. This robust 
multiplexed imaging approach introduces a new way to detect and locate engineered NPs. 
We have previously shown that LDI-MS can be used to analyze many different types of 
NPs, e.g., AuNPs, quantum dots, and magnetic NPs
24-29
 so imaging of these NPs should 
also be possible. We can also detect a wide range of surface functionalities with LDI-
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MS,
25
 which should make this imaging technique appropriate for a broad scope of 
nanomaterials. One improvement that needs to be made in the method is the ability to 
analyze NPs having ligands with higher molecular weights (> ~ 1000 Da).  Using this 
new "mass barcode" approach, we find that the intraorgan distribution of same-sized NPs 
is directly linked to their surface functionality, which is difficult to obtain using any other 
techniques. We envision that this described method will facilitate our understanding of 
the role of NP surface chemistry in nanomaterial-biological interactions by 
simultaneously comparing different NPs in a single model animal. This will minimize 
individual variances and thus provide insight into NP engineering, therapeutics, and 
diagnostics. Finally, the high sensitivity of this LDI-MS technique allows minimization 
of the tissue amount required for the detection, making this method a potential tool for 
clinical analyses of biopsies and microbiopsies. 
6.4 Experimental section 
Intravenous administration of AuNPs and collection of samples 
50 μL of each AuNP (2 μM) or AuNP mixture (concentration of each AuNP: 2 
μM) was administrated intravenously to Balb/c mice. After 24 h, the mice were humanely 
sacrificed by the inhalation of carbon dioxide and cervical dislocation. Then, the organ 
samples were harvested for analysis. Each organ was cut into two parts. One half was 
used for ICP-MS analysis to determine total gold amount, and the other half for LDI-MS 
imaging. 
LDI-MS imaging tissue preparation 
Leica cryostats (CM 3050 or 1850) were used to slice tissue. Tissues were sliced 
to 12 µm under -20 °C, and attached to ITO coated glass slides.  
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LDI-MS instrumentation and conditions 
LDI-MS imaging was carried out on a Bruker Autoflex III MALDI-TOF mass 
spectrometer (Bruker Daltonics, Bremen, Germany), which is equipped with a 
Smartbeam 2 Nd:YAG laser.  LDI-MS images were constructed using the FlexImaging 
2.1 software package. A total of 50 laser shots were measured per position. The step 
width between laser shots was 25 µm. The laser energy was optimized to ~ 61 µJ/pulse. 
Statistical evaluation 
Six areas of interest in the white pulp of the spleen tissue from a tumor-bearing 
mouse were analyzed using ImageJ software. Briefly, a ‘freehand selection’ function was 
employed to choose inside the white pulp areas and pixel frequencies were analyzed 
using a histogram function. Then, average pixel intensities were calculated using the 
equation as below:         
Only nonzero data containing pixels were counted and averaged for analysis 
following a reported method.
35
 One-way ANOVA was performed in the statistical 
evaluation, and the P values were 0.26 (AuNP 1 and 2), 8×10
-6
 (AuNP 2 and 3), and 
2×10
-5
 (AuNP 2 and 3), respectively. 
AuNP synthesis and characterization 
AuNPs were synthesized by the Brust-Schiffrin two-phase method.
36
 A Murray 
place exchange reaction followed to functionalize the NPs with different ligands.
37
 The 
synthesis of ligands has been reported in previous work.
24,38,39
  
The core sizes of the AuNPs used in this study were determined by TEM on a 
JEOL100S electron microscope (see panel a, b, and c in Figure 6.3). Dynamic light 
scattering (DLS) (see panel i, j, and k in Figure 6.3) and zeta-potential measurements of 
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AuNPs (see panel l, m, and n in  Figure 6.3) were obtained on a Malvern Nano Zetasizer 
(Nano series, Malvern Instruments Inc, USA) to evaluate quality and surface properties 
for the AuNPs. 2.5 µL of 2 µM solution of each AuNP was used for the LDI-MS 
characterization of surface ligands (Figure 6.4).   
Cell culture 
TD cells
40,41
 were cultured in Dulbecco's Modified Eagle's Medium/ Nutrient 
Mixture F-12 Ham (DMEM:F12, Sigma) supplemented with 25 mM of HEPES (Sigma), 
14 mM of NaHCO3, 2% bovine serum (Atlanta Biologicals, GA), 10 μg/mL of insulin 
(Sigma), 5 ng/mL of epidermal growth factor (EGF, Invitrogen, NY), 1% 
antibiotic/antimycotic solution (Gibco, NY), and 7.5 μg/mL of gentamicin (Gibco, NY). 
Animal care  
All animal experiments were conducted in accordance with the guidelines of 
Institutional Animal Care and Use Committee (IACUC) at University of Massachusetts-
Amherst. Female Balb/c mice were purchased from Jackson Laboratory (Bar Harbor, 
ME). Food and water intake were assessed. 
Intravenous administration of AuNPs in normal mice 
After one week of acclimatization, 50 μL of each AuNP (2 μM) was administered 
intravenously to each mouse (Balb/c, 10 weeks), while 50 μL of Dulbecco's phosphate-
buffered saline (DPBS) was administered intravenously in the control group. Mice were 
sacrificed and dissected 24 h after the intravenous administration of AuNPs. Mammary, 
brain, kidney, liver, spleen, lung, intestine, and heart were harvested and weighed for 
biodistribution and imaging.  
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Induction of mammary tumor and intravenous administration of AuNP 
mixture in tumor-induced mice    
After one week of acclimatization, the mice (Balb/c, 3 weeks) were anesthetized 
intraperitoneally by Avertin (Acros, 200 mg/kg). Prior to cell transplantation, an 
analgesic agent, buprenorphine (0.05 mg/kg), was subcutaneously administrated. After 
removing the skin hair with a trimmer (Braintree Scientific, MA), an inverted Y-shaped 
incision was made along the ventral thoracic-inguinal region to expose the mammary fat 
pad.
42
  Then, the region overlying the nipple and the mammary artery running between 
the 4th and 5th mammary glands were separately cauterized. The mammary fat pads were 
gently removed using curved forceps.  
TD cells (5x10
4
 cells/50 μL) were transplanted into the cleared fat pad using a 
Hamilton syringe. The skin was closed by wound clips (9 mm Autoclips Applier, 
Braintree Scientific, MA) and ethicon suture (Braintree Scientific, MA). The wound clips 
were removed approximately 1 week after the surgical procedure. After a mammary 
tumor was grown, the mixture of AuNPs was administered intravenously to each mouse. 
After 24 h, the mice were humanely sacrificed by the inhalation of carbon dioxide 
followed cervical dislocation. Then, each organ sample was harvested and further 
analyzed. After cutting them into two parts, one half was digested overnight to analyze 
for total gold amount (ng) by ICP-MS, and another half was used for the LDI-MS 
imaging. 
ICP-MS sample preparation and conditions  
Each organ was digested overnight using a 3:1 (v/v) mixture of HNO3 (75%) and 
H2O2 (25%). On the next day, ~0.5 mL of aqua regia was added, and then the sample 
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was diluted to 10 mL with de-ionized water. (Highly corrosive aqua regia must be added 
with extreme caution!) A series of standard solutions (gold concentration: 20, 10, 5, 2, 1, 
0.5, 0.2, 0 ppb) was prepared for each experiment. The ICP-MS analyses were performed 
on a Perkin-Elmer NexION 300X ICP mass spectrometer. 
197
Au was measured under 
standard mode. Operating conditions are listed as below: nebulizer flow rate: 0.95-1 
L/min; rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms.   
LDI-MS imaging tissue preparation  
A Leica cryostat CM 3050 and 1850 were used to slice all tissues. The tissues 
were sliced under -20 °C, and the optimal tissue thickness was found to be 12 µm. ITO 
coated glass slides (Delta Technologies, Limited, Loveland, CO).    
 
6.5 Supporting information 
 
 
Figure 6.10. LDI-MS images of AuNP 2 in mouse liver tissue. Left: LDI-MS image of 
gold ions; right: LDI-MS image of ligand ion from AuNP 2 (m/z = 492) (scale bar 
represents 1 mm). 
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Figure 6.11. H&E staining images of the splenic tissue. (Scale bar = 200 µm). 
 
 
 
Figure 6.12. Relative ionization efficiencies of AuNP 1-3. (a) A constant concentration 
of an internal standard AuNP (I.S.) was mixed with different concentrations of AuNP 1-3 
in cell lysates and then analyzed by LDI-MS. (b) The LDI-MS intensity ratios between 
AuNP 1-3 and I.S. were then plotted against the concentrations of AuNP 1-3. The 
resulting slopes for each NP provide a relative measure of their ionization efficiency 
because the same I.S. AuNP is used in each case. 
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Sensitivity of LDI-MS imaging 
We have evaluated the sensitivity of this new imaging technique using equation as 
below:                                              
Au
TissueAu
Au
i
M
dch
D
M
dV
n




2)
2
(
              （1） 
The amount of each AuNP (ni) per laser shot has been calculated using the 
volume of the sample for each LDI-MS measurement location (V), the density of the gold 
in the tissue (d) and the amount of gold in each AuNP (MAu). We measured the size of the 
laser burn (D) to be (45 ± 6) µm on the tissue after the LDI-MS imaging experiment by 
optical microscopy (Figure 6.13). The thickness of each tissue (h) is 12 µm, and thus the 
volume of the tissue sample for each LDI-MS measurement location is 19 pL. ICP-MS 
has been used to detect the concentration of gold in tissues (cAu) (Figure 6.5) and MAu. 
The cAu for AuNP 1, 2, and 3 used in the imaging experiments in Figure 6.6 are 5.34, 
5.95, and 5.72 μg/g, respectively. We assume the density of the tissue (dTissue) is 1.08 
g/cm
3
.
43
 Finally, as for sensitivity in tissues, the LDI-MS imaging technique has 
successfully detected 1.1, 1.3, and 1.2 attomol of AuNP 1, 2, and 3 used in this study, 
respectively. 
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Figure 6.13. Sensitivity determination of the LDI-MS imaging technique. (a) optical 
microscopy image of the laser burns on a 12 µm thickness splenic tissue. Laser 
stepwidth: 100 µm. Scale bar represents 100 µm. (b) laser burn size distribution (100 
measurements), size of the laser burns: (45 ± 6) µm. 
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